[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1103
1. Shackelford J, Pagano JS: Role of the ubiquitin system and tumor viruses in AIDS-related cancer. BMC Biochem; 2007;8 Suppl 1:S8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of the ubiquitin system and tumor viruses in AIDS-related cancer.
  • Tumor viruses are linked to approximately 20% of human malignancies worldwide.
  • This review focuses on examples of human oncogenic viruses that manipulate the ubiquitin system in a subset of viral malignancies; those associated with AIDS.
  • The viruses include Kaposi's sarcoma herpesvirus, Epstein-Barr virus and human papilloma virus, which are causally linked to Kaposi's sarcoma, certain B-cell lymphomas and cervical cancer, respectively.
  • We discuss the molecular mechanisms by which these viruses subvert the ubiquitin system and potential viral targets for anti-cancer therapy from the perspective of this system.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr HIV Res. 2004 Oct;2(4):343-9 [15544455.001]
  • [Cites] Cell Cycle. 2004 Nov;3(11):1345-7 [15492505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13057-62 [11087859.001]
  • [Cites] Acta Virol. 2000 Jun-Aug;44(3):211-26 [11155368.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1218-23 [11158620.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1227-35 [11423255.001]
  • [Cites] J Virol. 2001 Aug;75(16):7583-91 [11462030.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4740-9 [11498796.001]
  • [Cites] Chem Biol. 2001 Aug;8(8):739-58 [11514224.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):637-46 [11710679.001]
  • [Cites] J Cell Biol. 2001 Dec 24;155(7):1265-73 [11756476.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):6124-30 [11751860.001]
  • [Cites] Nat Med. 2002 Apr;8(4):338-40 [11927937.001]
  • [Cites] EMBO J. 2002 May 15;21(10):2418-29 [12006494.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]
  • [Cites] Oral Dis. 2002;8 Suppl 2:161-8 [12164651.001]
  • [Cites] Curr Top Microbiol Immunol. 2002;269:23-36 [12224511.001]
  • [Cites] Cancer Lett. 2002 Dec 15;188(1-2):15-24 [12406543.001]
  • [Cites] Virus Res. 2002 Nov;89(2):213-28 [12445661.001]
  • [Cites] Semin Cancer Biol. 2002 Dec;12(6):431-41 [12450729.001]
  • [Cites] Semin Cancer Biol. 2003 Feb;13(1):59-67 [12507557.001]
  • [Cites] Semin Cancer Biol. 2003 Feb;13(1):69-76 [12507558.001]
  • [Cites] J Pathol. 2003 Feb;199(2):140-5 [12533825.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):159-69 [12584163.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):307-12 [12619117.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Med Sci (Paris). 2003 Jan;19(1):100-6 [12836198.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):697-702, v-vi [12852651.001]
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] Isr Med Assoc J. 2004 Jul;6(7):420-4 [15274534.001]
  • [Cites] Trends Immunol. 2004 Aug;25(8):422-6 [15275641.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2003;21:717-46 [15338771.001]
  • [Cites] Semin Cancer Biol. 2004 Dec;14(6):453-71 [15489139.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Science. 1989 Feb 17;243(4893):934-7 [2537532.001]
  • [Cites] EMBO J. 1989 Dec 20;8(13):4099-105 [2556261.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):630-9 [15659509.001]
  • [Cites] Annu Rev Med. 2005;56:29-44 [15660500.001]
  • [Cites] Immunity. 2005 Jan;22(1):59-70 [15664159.001]
  • [Cites] Viral Immunol. 2004;17(4):473-80 [15671745.001]
  • [Cites] Cleve Clin J Med. 2005 Jan;72(1):73-8 [15691060.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Mar;53(3):253-65 [15718150.001]
  • [Cites] Curr Med Chem. 2005;12(3):357-74 [15723624.001]
  • [Cites] Expert Opin Emerg Drugs. 2005 Feb;10(1):5-19 [15757400.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:465-76 [15822185.001]
  • [Cites] J Virol. 2005 May;79(9):5705-12 [15827185.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):222-8 [15842046.001]
  • [Cites] Anticancer Drugs. 2005 Jun;16(5):475-81 [15846112.001]
  • [Cites] Cell Cycle. 2005 Feb;4(2):290-6 [15655370.001]
  • [Cites] Mem Inst Oswaldo Cruz. 2005 Feb;100(1):1-12 [15867955.001]
  • [Cites] AIDS Rev. 2005 Jan-Mar;7(1):56-61 [15875661.001]
  • [Cites] Oncologist. 2005 Jun-Jul;10(6):412-26 [15967835.001]
  • [Cites] Science. 2005 Jul 1;309(5731):127-30 [15994556.001]
  • [Cites] J Antimicrob Chemother. 2005 Aug;56(2):277-81 [16006448.001]
  • [Cites] EMBO J. 2006 Apr 19;25(8):1635-45 [16601694.001]
  • [Cites] Adv Dent Res. 2006;19(1):99-105 [16672559.001]
  • [Cites] Lancet. 2006 May 6;367(9521):1495-502 [16679162.001]
  • [Cites] Curr Mol Med. 2006 May;6(3):291-308 [16712476.001]
  • [Cites] Front Biosci. 2006;11:2672-713 [16720343.001]
  • [Cites] Cancer Treat Rev. 2006 Oct;32(6):445-55 [16860939.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9870-7 [17047048.001]
  • [Cites] Mol Cell Biol. 2007 Apr;27(8):2910-8 [17296724.001]
  • [Cites] Adv Cancer Res. 2000;78:1-29 [10547667.001]
  • [Cites] Oncogene. 1999 Dec 13;18(53):7690-700 [10618709.001]
  • [Cites] Virology. 2000 Mar 1;268(1):178-91 [10683340.001]
  • [Cites] Semin Cancer Biol. 1999 Dec;9(6):387-95 [10712885.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):717-45 [12852653.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3A):2133-8 [12894587.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5108-21 [12910248.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5122-30 [12910249.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6639-45 [14528289.001]
  • [Cites] Ann Med. 2003;35(6):404-12 [14572164.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15572-6 [14663138.001]
  • [Cites] AIDS Rev. 2003 Oct-Dec;5(4):222-9 [15012001.001]
  • [Cites] Oncogene. 2004 Mar 15;23(11):2107-15 [15021898.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):349-60 [15122206.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5089-93 [15169876.001]
  • [Cites] Curr Protein Pept Sci. 2004 Jun;5(3):153-61 [15180520.001]
  • [Cites] Oncologist. 2005 Aug;10(7):528-38 [16079320.001]
  • [Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Oct;56(1):155-67 [15979320.001]
  • [Cites] Antivir Ther. 2005;10(6):745-51 [16218174.001]
  • [Cites] Essays Biochem. 2005;41:139-56 [16250903.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18431-6 [16344472.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18562-6 [16352731.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]
  • [Cites] Ann Pharm Fr. 2005 Sep;63(5):343-9 [16385784.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1056:328-43 [16387699.001]
  • [Cites] Annu Rev Med. 2006;57:33-47 [16409135.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Feb;15(2):117-30 [16433592.001]
  • [Cites] Yonsei Med J. 2006 Feb 28;47(1):1-14 [16502480.001]
  • [Cites] Cancer Gene Ther. 2006 May;13(5):445-50 [16341140.001]
  • [Cites] Curr Med Chem. 2006;13(7):745-54 [16611064.001]
  • [Cites] Nihon Rinsho. 2006 Mar;64 Suppl 3:635-8 [16615550.001]
  • [Cites] Int J Oncol. 2000 May;16(5):853-70 [10762621.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):690-8 [10793105.001]
  • [Cites] Bioessays. 2000 May;22(5):442-51 [10797484.001]
  • [Cites] Clin Lab Med. 2000 Jun;20(2):383-406 [10863646.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6 [10859362.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Adv Pharmacol. 2000;49:479-514 [11013772.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(22):8526-35 [11046148.001]
  • [Cites] Cell. 1990 Dec 21;63(6):1129-36 [2175676.001]
  • [Cites] Hum Cell. 1992 Mar;5(1):25-41 [1329931.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Princess Takamatsu Symp. 1991;22:239-48 [1668886.001]
  • [Cites] Int J Cancer. 1993 Sep 9;55(2):208-12 [8370617.001]
  • [Cites] Hosp Pract (1995). 1996 Sep 15;31(9):41-8, 53-5, 59-60 [8814120.001]
  • [Cites] Mol Med Today. 1997 Jun;3(6):246-53 [9211415.001]
  • [Cites] Semin Cancer Biol. 1996 Dec;7(6):317-26 [9284524.001]
  • [Cites] J Biol Chem. 1997 Nov 28;272(48):30135-40 [9374493.001]
  • [Cites] FEBS Lett. 1997 Dec 22;420(1):25-7 [9450543.001]
  • [Cites] J Biol Chem. 1998 Mar 13;273(11):6439-45 [9497376.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Nature. 1998 Aug 6;394(6693):588-92 [9707121.001]
  • [Cites] Trends Microbiol. 1998 Jul;6(7):276-82 [9717216.001]
  • [Cites] Oncogene. 1998 Dec 10;17(23):2943-54 [9881696.001]
  • [Cites] Front Biosci. 1999 May 15;4:D468-75 [10331991.001]
  • (PMID = 18047745.001).
  • [ISSN] 1471-2091
  • [Journal-full-title] BMC biochemistry
  • [ISO-abbreviation] BMC Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ubiquitin
  • [Number-of-references] 119
  • [Other-IDs] NLM/ PMC2106372
  •  go-up   go-down


2. Fujimuro M: [Kaposi's sarcoma-associated herpesvirus and mechanisms of oncogenesis]. Uirusu; 2006 Dec;56(2):209-18
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Kaposi's sarcoma-associated herpesvirus and mechanisms of oncogenesis].
  • Kaposi's sarcoma-associated herpesvirus (KSHV, also known as human herpesvirus 8), is well known to be responsible for Kaposi's sarcoma, the most common AIDS-related cancer.
  • KSHV is also associated with the B cell malignancies primary effusion lymphoma and multicentric Castleman's disease.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17446670.001).
  • [ISSN] 0042-6857
  • [Journal-full-title] Uirusu
  • [ISO-abbreviation] Uirusu
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / E2F Transcription Factors; 0 / Receptors, Notch; 0 / Viral Proteins; 0 / Wnt Proteins
  • [Number-of-references] 47
  •  go-up   go-down


3. Sivakumaran H, van der Horst A, Fulcher AJ, Apolloni A, Lin MH, Jans DA, Harrich D: Arginine methylation increases the stability of human immunodeficiency virus type 1 Tat. J Virol; 2009 Nov;83(22):11694-703
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The stabilizing action of PRMT6 could allow Tat to persist within the cell and the extracellular environment and thereby enable functions implicated in AIDS-related cancer, neurodegeneration, and T-cell death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2006 Jan 27;124(2):381-92 [16439211.001]
  • [Cites] Retrovirology. 2009;6:1 [19128510.001]
  • [Cites] Mol Cell. 2006 Apr 7;22(1):51-62 [16600869.001]
  • [Cites] Microbes Infect. 2006 Apr;8(5):1347-57 [16697675.001]
  • [Cites] Retrovirology. 2006;3:48 [16893449.001]
  • [Cites] J Cell Biol. 2006 Nov 6;175(3):401-13 [17088425.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(1):120-34 [17043108.001]
  • [Cites] Nature. 2007 Jan 11;445(7124):214-8 [17215844.001]
  • [Cites] Retrovirology. 2006;3:93 [17176473.001]
  • [Cites] Mol Cell. 2007 Feb 9;25(3):369-83 [17289585.001]
  • [Cites] J Virol. 2007 Apr;81(8):4226-34 [17267505.001]
  • [Cites] AIDS. 2007 Apr 23;21(7):795-805 [17415034.001]
  • [Cites] Mol Cell. 2007 Jun 22;26(6):831-42 [17588518.001]
  • [Cites] Mol Cell. 2007 Jun 22;26(6):843-52 [17588519.001]
  • [Cites] Curr HIV Res. 2007 Sep;5(5):473-83 [17896967.001]
  • [Cites] Nature. 2007 Oct 18;449(7164):933-7 [17898714.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):6106-18 [10545121.001]
  • [Cites] Mol Ther. 2000 Oct;2(4):404-14 [11020357.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28179-84 [11384967.001]
  • [Cites] Mol Cell Biol. 2001 Dec;21(23):7956-70 [11689688.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3537-43 [11724789.001]
  • [Cites] EMBO J. 2002 Jul 1;21(13):3516-25 [12093752.001]
  • [Cites] J Cell Physiol. 2002 Aug;192(2):209-15 [12115727.001]
  • [Cites] Nat Biotechnol. 2003 Aug;21(8):921-6 [12872131.001]
  • [Cites] Nat Cell Biol. 2003 Aug;5(8):754-61 [12883554.001]
  • [Cites] Gene. 2004 Feb 4;326:1-11 [14729258.001]
  • [Cites] Eur J Clin Invest. 2004 Jan;34(1):57-66 [14984439.001]
  • [Cites] Cell. 2004 Jun 11;117(6):690-1 [15186770.001]
  • [Cites] Mol Cell. 2004 Aug 27;15(4):559-71 [15327772.001]
  • [Cites] J Mol Biol. 1971 Dec 28;62(3):465-77 [5136579.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Nature. 1990 May 3;345(6270):84-6 [2184372.001]
  • [Cites] Biotechniques. 1991 Dec;11(6):739-40, 742-3 [1809326.001]
  • [Cites] J Biol Chem. 1993 May 15;268(14):10501-9 [7683681.001]
  • [Cites] Arch Virol. 1994;137(1-2):149-55 [7979988.001]
  • [Cites] J Biol Chem. 1996 Mar 29;271(13):7844-50 [8631829.001]
  • [Cites] J Immunol. 1996 Aug 1;157(3):974-7 [8757599.001]
  • [Cites] J Biol Chem. 1997 Mar 28;272(13):8145-8 [9079628.001]
  • [Cites] EMBO J. 1997 Mar 17;16(6):1224-35 [9135139.001]
  • [Cites] Cell. 1998 Feb 20;92(4):451-62 [9491887.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):384-9 [9514931.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1998;61:65-131 [9752719.001]
  • [Cites] Virology. 1998 Dec 5;252(1):126-36 [9875323.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):353-60 [15525938.001]
  • [Cites] J Virol. 2005 Jan;79(1):124-31 [15596808.001]
  • [Cites] PLoS Biol. 2005 Feb;3(2):e41 [15719057.001]
  • [Cites] Endocr Rev. 2005 Apr;26(2):147-70 [15479858.001]
  • [Cites] Mol Cell. 2005 Apr 29;18(3):263-72 [15866169.001]
  • [Cites] J Exp Med. 2005 Aug 1;202(3):371-7 [16061726.001]
  • [Cites] J Immunol. 2005 Nov 15;175(10):6402-11 [16272292.001]
  • [Cites] Microbes Infect. 2005 Oct;7(13):1364-9 [16046164.001]
  • [Cites] Science. 2007 Oct 19;318(5849):444-7 [17947579.001]
  • [Cites] Genes Dev. 2007 Dec 15;21(24):3369-80 [18079182.001]
  • [Cites] Retrovirology. 2008;5:40 [18498648.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1433-9 [18418067.001]
  • [Cites] Biochim Biophys Acta. 2008 Sep;1780(9):1062-9 [18573314.001]
  • [Cites] Retrovirology. 2008;5:63 [18620576.001]
  • [Cites] J Biol Chem. 2006 Feb 17;281(7):3764-72 [16293633.001]
  • (PMID = 19726520.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / tat Gene Products, Human Immunodeficiency Virus; 94ZLA3W45F / Arginine; EC 2.1.1.- / PRMT6 protein, human; EC 2.1.1.- / Protein-Arginine N-Methyltransferases
  • [Other-IDs] NLM/ PMC2772670
  •  go-up   go-down


Advertisement
4. Cheung MC, Pantanowitz L, Dezube BJ: AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist; 2005 Jun-Jul;10(6):412-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.
  • Human immunodeficiency virus (HIV)-infected patients are at increased risk of developing cancer, particularly in the later stages of acquired immune deficiency syndrome (AIDS).
  • Despite the advent of highly active anti-retroviral therapy (HAART), malignancy in this population is a leading cause of morbidity and mortality.
  • Kaposi's sarcoma (KS) and AIDS-related non-Hodgkin's lymphoma (ARL) are the most common AIDS-defining malignancies.
  • AIDS-related KS varies from minimal to fulminant disease.
  • Treatment decisions for AIDS-related KS are guided largely by the presence and extent of symptomatic disease.
  • Novel therapies that have become available to treat AIDS-related KS include angiogenesis inhibitors and antiviral agents.
  • ARL comprises a heterogeneous group of malignancies.
  • HIV-infected patients also appear to be at increased risk for developing certain non-AIDS-defining cancers, such as Hodgkin's lymphoma and multiple myeloma.
  • Although the optimal treatment of these neoplasms is at present uncertain, recent advances in chemotherapy, antiretroviral drugs, and supportive care protocols are allowing for more aggressive management of many of the AIDS-related cancers.
  • This article provides an up-to-date review of the epidemiology, pathogenesis, clinical features, and treatment of various AIDS-related malignancies that are likely to be encountered by an oncologist practicing in the current HAART era.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Medical Oncology / trends. Sarcoma, Kaposi / drug therapy


5. Cáceres W, Cruz-Amy M, Díaz-Meléndez V: AIDS-related malignancies: revisited. P R Health Sci J; 2010 Mar;29(1):70-5
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: revisited.
  • Since the first reports between the association of Human Immunodeficiency Virus (HIV) infection and neoplasia, there has been a dramatic change in the incidence and epidemiology of AIDS-related malignancies.
  • Kaposi sarcoma (KS), non-Hodgkin's lymphomas (NHL), and cervical cancer are classified by the Centers for Disease Control and Prevention (CDC) as AIDS-defining malignancies.
  • However, since the availability of highly active combination antiretroviral therapy (cART), especially protease inhibitors, there has been a steady increase in non- AIDS defining malignancies, such as Hodgkin's lymphoma (HL), lung cancer, hepatocellular cancer, anal cancer and others and a decline in AIDS-defining neoplasias.
  • Although the emergence of non-AIDS defining cancers could be a result of longer life expectancy and due to a better control of HIV, toxic habits and co-infection with other viruses such as hepatitis B, hepatitis C and human papilloma virus (HPV) could play an important role.
  • The interactions of cART and incomplete immune reconstitution could be other factors explaining the increase in non-AIDS defining cancers.
  • These emerging non-AIDS defining malignancies present a new challenge in the care of patients with HIV infection, and require optimal treatment protocols that take into consideration the interaction between cART and systemic chemotherapy.
  • We review the current status of AIDS-related malignancies, its pathophysiology, epidemiology and management with emphasis in the changing patterns of presentation.
  • [MeSH-minor] Humans. Lymphoma, AIDS-Related / epidemiology


6. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA, HIV/AIDS Cancer Match Study: AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst; 2007 Jun 20;99(12):962-72
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related cancer and severity of immunosuppression in persons with AIDS.
  • BACKGROUND: The incidence of Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer has been declining among persons with AIDS.
  • We investigated the association between cancer risk and CD4 cell count among such persons.
  • METHODS: Data from US AIDS registries were linked to local cancer registry data.
  • Cancer incidence per 100,000 person-years was determined for the 4-27 months from the onset of AIDS from January 1, 1990, through December 31, 1995--before highly active antiretroviral therapy (HAART) became available--and from January 1, 1996, through December 31, 2002.
  • The relationships between CD4 count at AIDS onset and cancer incidence were assessed by proportional hazards models.
  • RESULTS: Among 325,516 adults with AIDS, the incidence of Kaposi sarcoma was lower in 1996-2002 (334.6 cases per 100,000 person-years) than in 1990-1995 (1838.9 cases per 100,000 person-years), and the incidence of non-Hodgkin lymphoma followed a similar pattern (i.e., 390.1 cases per 100,000 person-years in 1996-2002 and 1066.2 cases per 100,000 person-years in 1990-1995).
  • Cervical cancer incidence was higher in 1996-2002 (86.5 per 100,000 person-years) than in 1990-1995 (64.2 per 100,000 person-years), although not statistically significantly so (relative risk [RR] = 1.41, 95% CI = 0.81 to 2.46).
  • Similar relationships of these cancers to CD4 count were observed for 1990-1995.
  • CONCLUSIONS: Both before and after HAART was available, CD4 count was strongly associated with risks for Kaposi sarcoma and non-Hodgkin lymphoma but not for cervical cancer and Burkitt lymphoma.
  • The decreasing incidences of most AIDS-associated cancers in persons with AIDS during the 1990s are consistent with improving CD4 counts after HAART introduction in 1996.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / immunology. Sarcoma, Kaposi / immunology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565153.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


7. Schlichemeyer R, Chambers C, Gill MJ: The oncology impact of highly active antiretroviral therapy. J Oncol Pharm Pract; 2007 Mar;13(1):17-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To examine the impact of using highly active antiretroviral therapy (HAART) in a human immunodeficiency virus (HIV) infected population on the chemotherapy related costs of treating acquired immunodeficiency (AIDS)-related cancers.
  • METHODS: We used the Southern Alberta Clinic (SAC) database to define the incidence and prevalence of AIDS-related cancers in a geographically defined HIV population in both the pre- HAART and HAART eras, and subsequently, the Alberta Cancer Board Pharmacy database to determine the chemotherapy associated costs of the cancer treatment.
  • RESULTS: During both eras, 60% of AIDS-related cancer patients received chemotherapy.
  • The absolute number of patients treated in the pre-HAART era was 70, but during the HAART era, due to the decreased incidence of these cancers, only 13 patients received chemotherapy.
  • The number of distinct regimens used for AIDS cancer treatment standardised, and decreased from 29 to six between eras.
  • CONCLUSION: The introduction of HAART has dramatically reduced the amount spent on chemotherapy due to a decreased incidence of AIDSrelated cancers, even though the individual patient treatments have become more effective and expensive.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621563.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. Krishnan A, Forman SJ: Hematopoietic stem cell transplantation for AIDS-related malignancies. Curr Opin Oncol; 2010 Sep;22(5):456-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation for AIDS-related malignancies.
  • PURPOSE OF REVIEW: AIDS-related malignancies are an ongoing cause of mortality in individuals with HIV infection.
  • In the HIV-negative setting, high-dose chemotherapy or stem cell transplantation is an option for patients with hematologic malignancies.
  • RECENT FINDINGS: Early autologous stem cell transplantation has studies had high relapse rates but they demonstrated that mobilization and engraftment of autologous stem cells were possible in AIDS patients.
  • Recently, in less advanced AIDS lymphoma, autologous stem cell transplantation has resulted in low transplant-related mortality and durable remissions.
  • In addition, case-control studies of HIV-positive versus HIV-negative lymphoma patients undergoing autologous stem cell transplantation have shown similar transplant-related mortality and overall survival.
  • SUMMARY: The potential future applications of autologous and allogeneic stem cell transplantation are the cure of the malignancy as well as the underlying HIV infection by either transplantation of naturally resistant or genetically modified stem cells.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Jul 25;347(4):284-7 [12140307.001]
  • [Cites] Blood. 2009 Aug 13;114(7):1306-13 [19451551.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] Blood. 1989 Apr;73(5):1340-50 [2649174.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2466-72 [1933784.001]
  • [Cites] Bone Marrow Transplant. 1996 Dec;18(6):1195-7 [8971396.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3561-4 [10446961.001]
  • [Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):59-66 [18158962.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3484-7 [18698002.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2192-8 [19332732.001]
  • [Cites] Blood. 2009 Jun 4;113(23):6011-4 [19307667.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1521-9 [12824790.001]
  • (PMID = 20639760.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P50 CA107399
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS427480; NLM/ PMC3537514
  •  go-up   go-down


9. Orem J, Otieno MW, Remick SC: Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa. Curr Opin Oncol; 2006 Sep;18(5):479-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa.
  • PURPOSE OF REVIEW: Following our review of AIDS-associated cancer in developing nations in 2004, we sought to update recent publications and review data on the challenges and opportunities for the treatment and research of AIDS malignancies in Africa.
  • RECENT FINDINGS: It is apparent that the burden of AIDS-related malignancies and other virus-associated tumors is significant and increasing in Africa.
  • Several recent studies report findings on conjunctival squamous cell carcinoma and there is a report that Hodgkin's disease, a non-AIDS-defining neoplasm, is increasing in incidence.
  • International collaborative partnerships dedicated to AIDS malignancies in developing countries are feasible and invaluable for clinical strategies to address this aspect of the pandemic.
  • A departure point is the ongoing work of the East Africa - Case Western Reserve University Collaboration in AIDS malignancies.
  • SUMMARY: The burden of neoplastic complications of HIV infection and endemic virus-associated tumors are assuming increasing significance in Africa.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894296.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI36219; United States / NCI NIH HHS / CA / CA43703; United States / NCI NIH HHS / CA / CA70081; United States / NCI NIH HHS / CA / CA83528; United States / FIC NIH HHS / TW / TW00011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


10. Chaturvedi AK, Mbulaiteye SM, Engels EA: Underestimation of relative risks by standardized incidence ratios for AIDS-related cancers. Ann Epidemiol; 2008 Mar;18(3):230-4
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Underestimation of relative risks by standardized incidence ratios for AIDS-related cancers.
  • PURPOSE: Registry-based studies provide valuable data regarding cancer risk among people with HIV/AIDS (PWHA).
  • However, SIR may underestimate RR when HIV/AIDS prevalence in the general population or RR is high.
  • We quantified the extent of this underestimation for 3 AIDS-related cancers: Kaposi sarcoma (KS), central nervous system non-Hodgkin lymphoma (CNS NHL) and cervical cancer.
  • METHODS: We used data on cancer risk among PWHA from the U.S.
  • HIV/AIDS Cancer Match Study.
  • (1) SIRs calculated using pre-AIDS era (1973-1979) cancer incidence rates (SIRpre-AIDS) and (2) SIRs calculated after subtraction of cancers known to be among PWHA from general population rates (SIRexclusion).
  • RESULTS: For KS and CNS NHL, SIRs (117.8 and 133.9, respectively) calculated using overall general population rates substantially underestimated both SIRpre-AIDS (19,778 and 3,612, respectively) and SIRexclusion (657.7 and 536.4, respectively).
  • In contrast, the extent of underestimation was negligible for cervical cancer (SIR = 4.9 vs. SIRexclusion = 5.1).
  • However, SIRpre-AIDS and SIRexclusion estimates were more similar, indicating that SIR differences artifactually reflect differences in HIV/AIDS prevalence between males and females.
  • For KS and CNS NHL, trends across calendar time were weaker in SIRs than in SIRpre-AIDS and SIRexclusion.
  • SIRs must be interpreted cautiously when HIV/AIDS prevalence is high or varies across groups of interest.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Sarcoma, Kaposi / epidemiology. Uterine Cervical Neoplasms / epidemiology


11. Gercovich FG, Gil Deza E, Martin Reina G, Garcia Gerardi C, Abal M, Santillan D, Tognelli F, Calarame J, Rivarola E, Morgenfeld E: 300% increase rate in juvenile cancer cases unrelated to AIDS: Is it real? J Clin Oncol; 2009 May 20;27(15_suppl):e17535

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 300% increase rate in juvenile cancer cases unrelated to AIDS: Is it real?
  • : e17535 Background: Juvenile Cancer (JC) involves patients between 18 and 29 years old (adult pt less than 30 yo) and can be or not associated to AIDS.
  • The non-AIDS JC pt challenge the clinical oncologist in many ways: there are few preventive measures, avoiding delayed toxicities is mandatory (fertility, cognitive impairment) and there is a lack of evidence-based treatments for uncommon tumors.
  • The aim of this paper is to evaluate the incidence and clinical outcome of JC non AIDS related at the IOHM.
  • The inclusion criteria was: new cancer pt diagnosed between 18 and 29 yo.
  • DIAGNOSIS: Expected tumors 269 pt (80%) (testicular tumors = 89 pt; lymphoma = 75 pt; sarcoma = 35 pt; melanoma = 17 pt; others = 53), Unexpected tumors 67 pt (20%) (gastrointestinal = 23 pt; breast cancer = 17 pt; ovarian = 13 pt; head and neck = 7 pt; others = 7 pt).
  • 1) In our database, 336 cases of JC out of 12.828 new cancer patients between were found 2001 and 2008;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963795.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Ryan JL, Heckler C, Dakhil SR, Kirshner J, Flynn PJ, Hickok JT, Morrow GR: Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):9511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients.
  • We conducted a multi-site, phase II/III randomized, placebo-controlled, double-blind clinical trial to assess the efficacy of ginger for chemotherapy-related nausea in cancer patients at the University of Rochester-affiliated Community Clinical Oncology Program (CCOP) member sites.
  • METHODS: Cancer patients who experienced nausea following any chemotherapy cycle and were scheduled to receive at least three additional cycles were eligible.
  • The goal was to determine if ginger was more effective than placebo in controlling chemotherapy-related nausea in participants given a 5-HT<sub>3</sub> receptor antagonist antiemetic.
  • Breast (66%), alimentary (6.5%), and lung (6.1%) cancers were the most common cancer types.
  • CONCLUSIONS: Ginger supplementation at daily dose of 0.5g-1.0g significantly aids in reduction of nausea during the first day of chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964484.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. D'Olimpio JT, Chasen MR, Sharma R, Diego M, Gullo V, MacDonald N: Phase II study of AVR118 in the management of cancer related anorexia/cachexia. J Clin Oncol; 2009 May 20;27(15_suppl):e20631

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of AVR118 in the management of cancer related anorexia/cachexia.
  • : e20631 Background: AVR118 represents a new class of cytoprotective drugs in managing symptoms associated with anorexia\/ cachexia.
  • In a previous study in patients with advanced HIV-AIDS, an improvement in appetite, strength and alertness was noted.
  • The precise mechanism of action is not understood, but activity may be related to AVR118's adenosine based components.
  • OBJECTIVE: To determine the effect of AVR118 on appetite, early satiety and nutritional intake in patients with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961581.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Braiteh FS, Pratt G, Kurzrock R, Bruera E: Systematic review of research trends in cancer cachexia: Insights from the literature and funding agencies. J Clin Oncol; 2009 May 20;27(15_suppl):e17540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic review of research trends in cancer cachexia: Insights from the literature and funding agencies.
  • : e17540 Background: Cancer cachexia affects about 250,000 patients in the US worsening treatment outcome and quality of life.
  • To evaluate the scholar contribution to cancer cachexia, we analyzed the cachexia literature and funding support.
  • To examine the trend over time, we compared the publication rate in the field of cachexia to that of published manuscripts in reference fields (cancer, AIDS, Alzheimer's disease, and CHF).
  • In the last 5 years, the ratio of "review" articles in cachexia increased significantly (49%), compared to cancer (17%), and science publications (8%).
  • Unlike the of publications in reference fields, the increase in cachexia has been mostly due to the dominance of "review" articles (ratio of original/review of 0.928 in cachexia, versus 0.417 in CHF, 0.337 in Alzheimer and 0.206 in AIDS).
  • CONCLUSIONS: Advances in the field of original cancer cachexia research have been very limited, perhaps related to the lack of federal research funding support, which is on the decline.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963774.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Cuéllar Ponce de León LE Sr, Miranda Rosales LM Sr, Biminchumo Zagástegui C, Rosales Cusichaqui R, Flores C Sr, Mas López L Sr, León Chong J Sr: Human immunodeficiency virus/acquired immunodeficiency syndrome-related cancer in the pre- and post-highly active antiretroviral therapy era in a national cancer center of a resource-limited country: 1988 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):e20550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus/acquired immunodeficiency syndrome-related cancer in the pre- and post-highly active antiretroviral therapy era in a national cancer center of a resource-limited country: 1988 to 2007.
  • : e20550 Background: The introduction of the highly active antiretroviral therapy (HAART) has changed the clinical course of acquired immune deficiency syndrome (AIDS) related to cancer.
  • The goals were to describe the the characteristics of AIDS related to cancer before and after HAART in patients in a Hospital of a resource-limited country.
  • The number of invasive cervical cancer (CC) and AIDS-related lymphomas (ARLs) increased in the Post HAART era; the number on non-HIV/AIDS related to cancer has decreased.
  • CONCLUSIONS: The introduction of HAART has reduced the number of non-VIH/AIDS related cancer, but have increased the CC and LNH and improved the survival of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961054.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Lou J, Ruggeri T, Tebaldi C: Modeling cancer in hiv-1 infected individuals: equilibria, cycles and chaotic behavior. Math Biosci Eng; 2006 Apr;3(2):313-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling cancer in hiv-1 infected individuals: equilibria, cycles and chaotic behavior.
  • For HIV-infected individuals, cancer remains a significant burden.
  • Gaining insight into the epidemiology and mechanisms that underlie AIDS- related cancers can provide us with a better understanding of cancer immunity and viral oncogenesis.
  • In this paper, an HIV-1 dynamical model incorporat- ing the AIDS-related cancer cells was studied.
  • The model consists of three components, cancer cells, healthy CD4+ T lymphocytes and infected CD4+ T lymphocytes, and can have six steady states.
  • We discuss the existence, the stability properties and the biological meanings of these steady states, in par- ticular for the positive one: cancer-HIV-healthy cells steady state.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20361826.001).
  • [ISSN] 1547-1063
  • [Journal-full-title] Mathematical biosciences and engineering : MBE
  • [ISO-abbreviation] Math Biosci Eng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Williams CK: HIV/AIDS pandemic (AP) in Africa: Chronicle of a missed opportunity. J Clin Oncol; 2009 May 20;27(15_suppl):e22235

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV/AIDS pandemic (AP) in Africa: Chronicle of a missed opportunity.
  • : e22235 Background: AP unlike HTLV-I associated diseases arrived late in parts of Africa, including Nigeria, where retroviral research was already ongoing in collaboration with the US National Cancer Institute (USNCI), thus providing unique preventive interventional opportunity.
  • Assuming 20 HIV-1+ = 1 case of AIDS death, SWB- determined SPR predicted (∼12-24)×10<sup>3</sup> AIDS deaths among 48×10<sup>6</sup> AGNP in 1985-86, ∼5 of (2.4- 4.8)×10<sup>3</sup> (<0.2%) of whom presented with clinical AIDS features (CAF) at Nigeria's premier health institution (NPHI).
  • Reports of SPR of 7.7 and 60.0 in AGNP and FCSW in 1996-2000 contrast against contemporary Ugandan SPR (14.0 down to 6.1) and Senegalese (0.4 up to 0.9), probably resulting from varying knowledge gap and angst-related inertia, illustrating mixed fortunes of AP in Africa, transcontinental variation in AP control capability, and providing lessons for the management of future public health challenges.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964112.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Sampaio J, Brites C, Araujo I, Bacchi CE, Dittmer DP, Tanaka PY, Harrington W Jr, Netto EM: AIDS related malignancies in Brazil. Curr Opin Oncol; 2007 Sep;19(5):476-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS related malignancies in Brazil.
  • PURPOSE OF REVIEW: There have been relatively few studies of HIV-related malignancies in Brazil.
  • Universal access to antiretroviral drugs in Brazil has changed both the mortality and morbidity rates of AIDS.
  • Nevertheless, there is also extreme poverty in both urban and rural areas and complications of prolonged immune suppression such as mycobacterial and malignant diseases have put a significant strain on the country's healthcare system.
  • This brief review outlines the existing data regarding AIDS related malignancies in the largest Latin American country.
  • In the studies done of HIV malignancies in Brazil, it appears that these tumors are histologically similar to those that occur in other equatorial countries and differ somewhat from those seen in Europe and the US.
  • SUMMARY: The existence of federally sponsored highly active antiretroviral therapy, clinicians and healthcare providers experienced in the care of HIV patients and high incidence of malignancies associated with oncogenic viruses make Brazil an important site for clinical and basic research in AIDS and immunodeficiency related malignancies.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2005 Oct;19 Suppl 4:S27-30 [16249650.001]
  • [Cites] East Afr Med J. 2005 Sep;82(9 Suppl):S133-4 [16619688.001]
  • [Cites] J Med Virol. 2006 Jun;78(6):719-23 [16628586.001]
  • [Cites] Braz J Med Biol Res. 2006 May;39(5):573-80 [16648893.001]
  • [Cites] Int J Hematol. 2006 Nov;84(4):337-42 [17118760.001]
  • [Cites] Pathol Res Pract. 2007;203(1):1-7 [17157997.001]
  • [Cites] J Infect Dis. 2000 May;181(5):1562-8 [10823754.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] J Clin Microbiol. 2002 Sep;40(9):3341-5 [12202576.001]
  • [Cites] Int J Dermatol. 2004 Sep;43(9):643-7 [15357742.001]
  • [Cites] AIDS Patient Care STDS. 1998 Aug;12(8):619-23 [15468433.001]
  • [Cites] J Acquir Immune Defic Syndr. 1993 Aug;6(8):959-63 [8315579.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):230-7 [8607450.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] J Infect Dis. 1998 Nov;178(5):1488-91 [9780272.001]
  • [Cites] J Gen Virol. 2005 Sep;86(Pt 9):2433-7 [16099900.001]
  • [Cites] Int J Infect Dis. 2005 Sep;9(5):239-50 [16095940.001]
  • (PMID = 17762574.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070058; United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / CA109232-03S1; United States / FIC NIH HHS / TW / D43 TW000017; United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / R01 CA163217; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / R01 CA109232-04; United States / NCI NIH HHS / CA / CA109232-03; United States / NCI NIH HHS / CA / CA109232-01; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NCI NIH HHS / CA / CA109232-02; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232-02; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / CA70058; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / R01 CA109232-01; United States / NCI NIH HHS / CA / R01 CA109232-03S1; United States / NCI NIH HHS / CA / R01 CA109232-03; United States / NIDCR NIH HHS / DE / DE018304-03; United States / NCI NIH HHS / CA / CA109232-04; United States / FIC NIH HHS / TW / 5D43 TW00017-18
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  • [Other-IDs] NLM/ NIHMS191349; NLM/ PMC2855639
  •  go-up   go-down


19. Noguchi K, Fukazawa H, Murakami Y, Takahashi N, Yamagoe S, Uehara Y: Gamma-herpesviruses and cellular signaling in AIDS-associated malignancies. Cancer Sci; 2007 Sep;98(9):1288-96
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma-herpesviruses and cellular signaling in AIDS-associated malignancies.
  • gamma-Herpesviruses, Epstein-Barr virus (EBV/HHV-4) and Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8), are involved in human carcinogenesis, particularly in immunocompromised patients.
  • Virus-associated malignancies are becoming of significant concern for the mortality of long-lived immunocompromised patients, and therefore, research of advanced strategies for AIDS-related malignancies is an important field in cancer chemotherapy.
  • Detailed understanding of the EBV and KSHV lifecycle and related cancers at the molecular level is required for novel strategies of molecular-targeted cancer chemotherapy.
  • The present review gives a simple outline of the functional interactions between KSHV- and EBV-viral gene products and host cell deregulated signaling pathways as possible targets of chemotherapy against AIDS-related malignancies.
  • [MeSH-major] Herpesvirus 4, Human / pathogenicity. Herpesvirus 8, Human / pathogenicity. Lymphoma, AIDS-Related / metabolism. Lymphoma, AIDS-Related / virology. Sarcoma, Kaposi / metabolism. Sarcoma, Kaposi / virology. Signal Transduction / physiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640300.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 102
  •  go-up   go-down


20. Warley E, Tamayo Antabak N, Desse J, De Luca A, Warley F, Fernández Galimberti G, D'Agostino G, Quintas L, Szyld E: [Development of AIDS-related malignancies and infections after starting HAART]. Medicina (B Aires); 2010;70(1):49-52
Hazardous Substances Data Bank. AZITHROMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Development of AIDS-related malignancies and infections after starting HAART].
  • In order to evaluate the incidence rate and possible risk factors associated with AIDS-related malignancies and infections (ARMI) we performed data analysis of clinical charts of HIV patients in two hospital cohorts, that started high activity antiretroviral therapy (HAART) between July 2003 and October 2007.
  • A CD4 cell count < 100/150 was associated with risk of developing ARMI.
  • TB in first place and cryptococcosis in second were the AIDS events more frequently observed.
  • A low CD4 cell count was the only observed risk factor statistically associated with development of ARMI.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active. Neoplasms / epidemiology


21. Sasco AJ, Jaquet A, Boidin E, Ekouevi DK, Thouillot F, Lemabec T, Forstin MA, Renaudier P, N'dom P, Malvy D, Dabis F: The challenge of AIDS-related malignancies in sub-Saharan Africa. PLoS One; 2010;5(1):e8621
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The challenge of AIDS-related malignancies in sub-Saharan Africa.
  • BACKGROUND: With the lengthening of life expectancy among HIV-positive subjects related to the use of highly active antiretroviral treatments, an increased risk of cancer has been described in industrialized countries.
  • The objective of our paper is to review the link between HIV and cancer in sub-Saharan Africa, putting it in perspective with what is already known in Western countries.
  • METHODS AND FINDINGS: Studies for this review were identified from several bibliographical databases including Pubmed, Scopus, Cochrane, Pascal, Web of Science and using keywords "HIV, neoplasia, epidemiology and Africa" and related MesH terms.
  • A clear association was found between HIV infection and AIDS-classifying cancers.
  • The association was less strong for invasive cervical cancer with ORs ranging from 1.1 (0.7-1.2) to 1.6 (1.1-2.3), whereas ORs for squamous intraepithelial lesions were higher, from 4.4 (2.3-8.4) to 17.0 (2.2-134.1).
  • For non AIDS-classifying cancers, squamous cell conjunctival carcinoma of the eye was associated with HIV in many case-referent studies with ORs from 2.6 (1.4-4.9) to 13.0 (4.5-39.4).
  • Other cancer sites found positively associated with HIV include lung, liver, anus, penis, vulva, kidney, thyroid and uterus and a decreased risk of female breast cancer.
  • CONCLUSION: Studies conducted in sub-Saharan Africa show that HIV infection is not only strongly associated with AIDS-classifying cancers but also provided some evidence of association for other neoplasia.
  • African countries need now to implement well designed population-based studies in order to better describe the spectrum of AIDS-associated malignancies and the most effective strategies for their prevention, screening and treatment.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 1995 Aug;21 Suppl 1:S121-4 [8547501.001]
  • [Cites] AIDS. 1996 Apr;10(4):413-7 [8728046.001]
  • [Cites] Br J Ophthalmol. 1996 Jun;80(6):503-8 [8759259.001]
  • [Cites] Lancet. 1996 Aug 31;348(9027):587-91 [8774574.001]
  • [Cites] Tumori. 1995 Sep-Oct;81(5):308-14 [8804445.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):73-7 [9037556.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1996;67:1-424 [9190379.001]
  • [Cites] Lancet. 1997 Nov 15;350(9089):1425-31 [9371165.001]
  • [Cites] Am J Clin Nutr. 2004 Nov;80(5):1106-22 [15531656.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):37-42 [9709301.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):817-20 [9714046.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] AIDS. 1998 Oct 1;12(14):1921-5 [9792393.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1521-8 [9836488.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] Int J Gynaecol Obstet. 1999 May;65(2):171-81 [10405062.001]
  • [Cites] Sex Transm Infect. 1999 Apr;75(2):103-6 [10448362.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):489-92 [11054682.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Oncol Rep. 2001 May-Jun;8(3):659-61 [11295098.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):622-7 [11340563.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1188-201 [11423251.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):430-5 [11433410.001]
  • [Cites] Int J Gynecol Cancer. 2001 May-Jun;11(3):194-7 [11437924.001]
  • [Cites] Int J Gynaecol Obstet. 2002 Jan;76(1):55-63 [11818095.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Br J Cancer. 2002 Jul 29;87(3):301-8 [12177799.001]
  • [Cites] AIDS. 2003 Jan 3;17(1):81-7 [12478072.001]
  • [Cites] Lancet. 2002 Dec 14;360(9349):1921-6 [12493258.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] Sex Transm Dis. 2003 Feb;30(2):137-42 [12567172.001]
  • [Cites] J Womens Health (Larchmt). 2003 Apr;12(3):227-32 [12804353.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2005 Apr;19(2):269-76 [15778115.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5224-8 [16051964.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):985-90 [16106415.001]
  • [Cites] Rev Med Interne. 2006 Mar;27(3):227-35 [16337065.001]
  • [Cites] Ann Oncol. 2006 Jun;17(6):914-9 [16565210.001]
  • [Cites] BMC Cancer. 2006;6:135 [16719902.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):355-62 [16832413.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):69-75 [16916294.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):642-8 [16868538.001]
  • [Cites] Cancer Lett. 2006 Nov 28;244(1):1-7 [16542773.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Transplant Proc. 2006 Dec;38(10):3533-5 [17175324.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] J Viral Hepat. 2007 Mar;14(3):183-8 [17305884.001]
  • [Cites] Pediatr Blood Cancer. 2007 May;48(5):515-20 [16794998.001]
  • [Cites] Am J Obstet Gynecol. 2007 Apr;196(4):407.e1-8; discussion 407.e8-9 [17403438.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1480-3 [17437020.001]
  • [Cites] Gynecol Obstet Invest. 2007;63(4):222-8 [17191009.001]
  • [Cites] J Med Virol. 2007 Jun;79(6):758-65 [17457908.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] Cancer Causes Control. 2008 Mar;19(2):147-53 [17992576.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636 [18354839.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2260-5 [18241034.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2590-3 [18224690.001]
  • [Cites] J Med Virol. 2008 May;80(5):847-55 [18360898.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Lancet. 2008 May 3;371(9623):1504 [18456099.001]
  • [Cites] AIDS. 1999 Dec 24;13(18):2563-70 [10630526.001]
  • [Cites] AIDS. 1999 Dec 24;13(18):2583-8 [10630528.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] J Natl Med Assoc. 2000 Jun;92(6):301-5 [10918766.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2401-8 [9635533.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Bull Cancer. 2003 May;90(5):387-92 [12850760.001]
  • [Cites] J Infect Dis. 2003 Aug 15;188(4):555-63 [12898443.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):84-90 [14501799.001]
  • [Cites] Int J STD AIDS. 2003 Oct;14(10):647-51 [14596765.001]
  • [Cites] Hepatology. 2004 Jan;39(1):211-9 [14752840.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):638-45 [14760378.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2644-54 [15197808.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] Curr Opin Oncol. 2004 Sep;16(5):468-76 [15314517.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] Lancet. 1982 May 1;1(8279):1026-7 [6122840.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1987 Aug 14;36 Suppl 1:1S-15S [3039334.001]
  • [Cites] Lancet. 1990 Jul 7;336(8706):51-2 [1973230.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Ann Intern Med. 1992 Aug 15;117(4):309-11 [1637026.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):26-36 [8478145.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • [Cites] Int J Cancer. 1994 Oct 1;59(1):20-4 [7927898.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Lancet. 1995 Mar 18;345(8951):695-6 [7885126.001]
  • [Cites] AIDS. 1995 Jan;9(1):57-63 [7893442.001]
  • [Cites] Lancet. 1995 May 27;345(8961):1378-9 [7752795.001]
  • [Cites] Int J Cancer. 1995 Sep 27;63(1):29-36 [7558448.001]
  • (PMID = 20066157.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI069919
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2799672
  •  go-up   go-down


22. Arora A, Chiao E, Tyring SK: AIDS malignancies. Cancer Treat Res; 2007;133:21-67
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS malignancies.
  • Among individuals with HIV-infection, coinfection with oncogenic viruses including EBV, HHV-8, and HPV cause significant cancer-related morbidity and mortality.
  • It is clear that these viruses interact with HIV in unique ways that predispose HIV-infected individuals to malignant diseases.
  • In general, treatment directed specifically against these viruses does not appear to change the natural history of the malignant disease, and once the malignancy develops, if their health permits, HIV-infected patients should be treated using similar treatment protocols to HIV-negative patients.
  • However, for the less frequent HIV-related malignancies, such as PEL, or MCD, optimal treatments are still emerging.
  • For certain AIDS-defining malignancies, it is clear that the widespread access to HAART has significantly decreased the incidence, and improved outcomes.
  • However, for other cancers, such as the HPV-related tumors, the role of HAART is much less clear.
  • Further research into prevention and treatment of these oncogenic virally mediated AIDS-related malignancies is necessary.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672037.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 368
  •  go-up   go-down


23. Biggar RJ, Engels EA, Ly S, Kahn A, Schymura MJ, Sackoff J, Virgo P, Pfeiffer RM: Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr; 2005 Jul 1;39(3):293-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after cancer diagnosis in persons with AIDS.
  • The survival of persons with AIDS (PWA) has recently improved because of better antiretroviral therapies.
  • Similarly, the prognosis of cancer has also improved.
  • To determine if survival in PWA with cancer has also improved, we compared cancer survival in adults with and without AIDS using data from New York City from 1980 through 2000.
  • Analyses were made for AIDS-related cancers (Kaposi sarcoma, non-Hodgkin lymphoma [NHL], and cervical cancer) and for 8 non-AIDS-related cancers (lung, larynx, colorectum, anus, Hodgkin lymphoma, breast, prostate, and testis).
  • Death hazard ratios compared survival in PWA with cancer with that in cancer patients without AIDS, adjusted for age, sex, race, and calendar-time of cancer occurrence.
  • The 24-month survival rate of PWA with cancer (9015 AIDS cancers and 929 non-AIDS-related cancers of 8 types) improved significantly for most cancer types.
  • By 1996 through 2000, the 24-month survival rate in PWA was 58% for Kaposi sarcoma, 41% for peripheral NHL, 29% for central nervous system NHL, and 64% for cervical cancer.
  • For non-AIDS-related cancers, survival of PWA was lowest for lung cancer (10%) but was >50% for most other cancer types.
  • In 1996 through 2000, significant differences in survival between cancer patients with and without AIDS still remained for Hodgkin lymphoma and lung, larynx, and prostate cancers.
  • We conclude that recent improvements in AIDS and cancer care have greatly narrowed the gap in survival between cancer patients with and without AIDS.
  • Clinicians should be encouraged by the improving prognosis and be diligent about detecting and treating cancer in PWA.
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. Female. Humans. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / mortality. Male. New York City / epidemiology. Prognosis. Registries. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / mortality. Survival Rate

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15980688.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Tirado-Ramos A, Saltz J, Lechowicz MJ: HIV-K: an integrative knowledge base for semantic integration of AIDS-related malignancy data and treatment outcomes. Stud Health Technol Inform; 2010;159:239-43
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-K: an integrative knowledge base for semantic integration of AIDS-related malignancy data and treatment outcomes.
  • Technological innovations such as web services and collaborative Grid platforms like caGrid can create opportunities to converge the worlds of health care and clinical research, by facilitating access and integration of HIV-related malignancy clinical and outcomes data at more sophisticated, semantic levels.
  • At the same time, large numbers of randomized clinical trial and outcomes data on AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) have been produced during the last few years.
  • This is a white paper on work in progress from Emory University's HIV/AIDS related malignancy data integrative knowledge base project (HIV-K).
  • We are working to increase the understanding of available clinical trial data and outcomes of ADM such as lymphoma, as well as nADM such as anal cancer, Hodgkin lymphoma, or liver cancer.
  • Our hypothesis is that, by creating prototypes of tools for semantics-enabled integrative knowledge bases for HIV/AIDS-related malignancy data, we will facilitate the identification of patterns and potential new overall evidence, as well as the linking of integrated data and results to registries of interest.
  • [MeSH-major] Databases, Factual. HIV-1. Lymphoma, AIDS-Related / therapy. Semantics

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - How to Tell Patients .
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2008 Dec 1;112(12):4384-99 [19029456.001]
  • [Cites] PLoS One. 2009;4(3):e4724 [19266092.001]
  • [Cites] J Clin Exp Neuropsychol. 2010 Apr;32(4):398-407 [19763997.001]
  • [Cites] Int J STD AIDS. 1999 Dec;10(12):795-802 [10639060.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Stat Med. 1988 Nov;7(11):1121-37 [3201038.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Public Health. 2005;95 Suppl 1:S144-50 [16030331.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim [16396154.001]
  • [Cites] Bioinformatics. 2006 Aug 1;22(15):1910-6 [16766552.001]
  • [Cites] Antiviral Res. 2006 Sep;71(2-3):335-42 [16782210.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • (PMID = 20543443.001).
  • [ISSN] 0926-9630
  • [Journal-full-title] Studies in health technology and informatics
  • [ISO-abbreviation] Stud Health Technol Inform
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI050409; United States / NIAID NIH HHS / AI / P30 AI050409; United States / NIAID NIH HHS / AI / P30 AI050409-11; United States / NCRR NIH HHS / RR / UL1 RR025008; United States / NCRR NIH HHS / RR / UL1 RR025008-04; United States / NCATS NIH HHS / TR / UL1 TR000454
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS315000; NLM/ PMC3157699
  •  go-up   go-down


25. Phatak UA, Joshi R, Badakh DK, Gosavi VS, Phatak JU, Jagdale RV: AIDS-associated cancers: an emerging challenge. J Assoc Physicians India; 2010 Mar;58:159-62
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated cancers: an emerging challenge.
  • OBJECTIVES: To study the incidence and effects of anti-retroviral therapy along with cancer chemotherapy on outcome of AIDS associated Cancers in Indian patients.
  • METHOD: 3832 cancers patients were investigated over a period of 5 years.
  • 46 AIDS-associated cancers were identified.
  • Patients were treated with different modalities of cancer management and anti-retroviral therapy was discussed with the patient and relatives.
  • RESULTS: Incidence of AIDS-associated cancers was 1.2 percent.
  • AIDS-Defining Cancers (ADC) were seen in 26 (54.35%) while non-AIDS-Defining Cancers (NADC) were observed in 21 (45.65%).
  • Non Hodgkin Lymphoma was the commonest form of AIDS-defining cancers in 21 (84%) patients, cervical cancers in 4 (16%) women while there was not a single case of Kaposi's Sarcoma.
  • AIDS associated cancers were common in males.
  • Only 33.5% patients received treatment for HIV and cancers.
  • CONCLUSIONS: AIDS-associated cancers are seen in advanced stage of HIV infection.
  • Cervical cancers and non-AIDS-defining cancers do not show predictable response to anti-retroviral therapy.
  • Mortality in non-AIDS related cancers was significantly higher than AIDS related cancers.


26. Yarchoan R, Tosato G, Little RF: Therapy insight: AIDS-related malignancies--the influence of antiviral therapy on pathogenesis and management. Nat Clin Pract Oncol; 2005 Aug;2(8):406-15; quiz 423
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy insight: AIDS-related malignancies--the influence of antiviral therapy on pathogenesis and management.
  • Patients with HIV infection are at an increased risk of a number of malignancies, including Kaposi's sarcoma (KS) and certain B-cell lymphomas.
  • Most of these tumors are caused by oncogenic DNA viruses, including KS-associated herpesvirus and Epstein-Barr virus.
  • The development of highly active antiretroviral therapy (HAART) has reduced the incidence of many HIV-associated tumors and has generally improved their responsiveness to therapy.
  • However, the number of people living with AIDS is increasing, and it is possible that the number of AIDS-associated malignancies will rise and the pattern of tumors will change as more people live longer with HIV infection.
  • By contrast, the goal of AIDS-related lymphoma therapy in most cases is the attainment of a complete response with curative intent, and the benefits of administering HAART during therapy must be weighed against possible disadvantages.
  • The past decade has seen substantial improvements in the treatment of AIDS-related lymphoma, which is attributed partially to a shift in tumor type and more effective regimens.
  • There is currently an interest in developing new therapies for HIV-associated malignancies, based on viral, vascular or other pathogenesis-based targets.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / physiopathology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / physiopathology. Sarcoma, Kaposi / virology


27. Neuman HB, Charlson ME, Temple LK: Is there a role for decision aids in cancer-related decisions? Crit Rev Oncol Hematol; 2007 Jun;62(3):240-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for decision aids in cancer-related decisions?
  • Cancer-related decisions are challenging, requiring patients to evaluate associated medical and psychological outcomes within the context of their personal values.
  • Clinical decision aids are decisional support tools designed to facilitate patient-driven decision-making by providing relevant information on the options while eliciting and incorporating patient preferences; they have been designed to support decision-making in the prevention, screening, and treatment of cancer.
  • In randomized controlled trials, cancer-related decision aids have been shown to increase patients' knowledge regarding their disease, and may facilitate patients playing a more active role in decision-making.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317206.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 93
  •  go-up   go-down


28. Lim ST, Levine AM: Non-AIDS-defining cancers and HIV infection. Curr HIV/AIDS Rep; 2005 Aug;2(3):146-53
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-defining cancers and HIV infection.
  • With fewer patients now succumbing to infectious complications of AIDS, other HIV-related morbidities, such as malignancies, have become increasingly important.
  • Apart from Kaposi's sarcoma, non-Hodgkin's lymphoma, and cervical cancer, which are considered as AIDS-defining, several additional cancers, referred to as non-AIDS-defining cancers, are also statistically increased in HIV-infected persons.
  • These include Hodgkin's disease, anal carcinoma, lung cancer, nonmelanomatous skin cancer, and testicular germ cell tumors, among others.
  • However, the types of cancer observed at an increased frequency and the relative risks reported vary widely among studies.
  • Although immunosuppression is consistently associated with an increased risk of AIDS-related malignancies, the role of immunosuppression in the pathogenesis of non-AIDS- defining cancers is controversial.
  • Although data regarding the optimal management of these cancers are lacking, current studies suggest that patients with HIV-associated malignancies should be treated with similar approaches to those of their counterparts in the general population.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Eur J Epidemiol. 1995 Dec;11(6):609-14 [8861842.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):367-71 [12607641.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):444-50 [11035615.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Apr;5(2):343-56 [2022598.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1602-8 [9362158.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] AIDS Care. 1996 Feb;8(1):5-14 [8664369.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):635-41 [8240994.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2540-6 [7595705.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2705-11 [7595728.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2739-45 [11753946.001]
  • [Cites] Int J STD AIDS. 2001 Feb;12(2):100-2 [11236097.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):432-6 [1617592.001]
  • [Cites] Cancer. 1990 May 15;65(10):2248-54 [2346909.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):189-95 [10093688.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):563-9 [10649248.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1391-7 [7538557.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1348-9; author reply 1349-50 [15051794.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):292-8 [12856222.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):480-8 [10950375.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):997-1010 [8880192.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] Chest. 1993 Feb;103(2):410-3 [8432128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Sep;11(9):1587-93 [3928544.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12667-71 [11058153.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Chest. 1998 Jan;113(1):154-61 [9440583.001]
  • [Cites] Mutat Res. 1999 Oct 19;429(2):249-59 [10526209.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1922-7 [12743144.001]
  • [Cites] Fundam Appl Toxicol. 1996 Aug;32(2):148-58 [8921318.001]
  • [Cites] Mutagenesis. 2000 Sep;15(5):405-10 [10970446.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:201-5 [1710920.001]
  • [Cites] Lung Cancer. 2002 Apr;36(1):9-14 [11891027.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):457-9 [12888811.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1520-4 [8944046.001]
  • [Cites] Chest. 1992 Dec;102(6):1704-8 [1446476.001]
  • (PMID = 16091262.001).
  • [ISSN] 1548-3568
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


29. Rochford R, Feuer G, Orem J, Banura C, Katongole-Mbidde E, Mwanda WO, Moormann A, Harrington WJ, Remick SC: Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma. East Afr Med J; 2005 Sep;82(9 Suppl):S155-60
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma.
  • BACKGROUND: Strategies to circumvent or lessen the myelotoxicity associated with combination chemotherapy may improve the overall outcome of the management of patients particularly in resource poor settings.
  • OBJECTIVES: To develop effective non-myelotoxic therapies for Burkitt's Lymphoma (BL) and AIDS-related non-Hodgkin's lymphoma.
  • CONCLUSION: Myelotoxic death rates using multi-agent induction chemotherapy approach 25% for endemic Burkitt's lymphoma and range between 20% to 60% for AIDS-related malignancy.
  • This is mostly explained by the paucity of supportive care compounded by wasting and inanition attributable to advanced cancer and HIV infection making patients more susceptible to myelosuppressive side effects of cytotoxic chemotherapy.
  • Investigations and alternative approaches that lessen or circumvent myelotoxicity of traditional cytotoxic chemotherapy for the management of Burkitt's lymphoma and AIDS-related non-Hodgkin's lymphoma in the resource-constrained setting are warranted.
  • This can be achieved by developing targeted anti-viral and other strategies, such as the use of bryostatin 1 and vincristine, and by developing a preclinical mouse model to frame the clinical rationale for a pilot trial of metronomic therapy for the treatment of Burkitt's and AIDS-related lymphoma.
  • Implementation of these investigational approaches must be encouraged as viable anti-cancer therapeutic strategies particularly in the resource-constrained settings.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy. Macrolides / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619692.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bryostatins; 0 / Macrolides; 37O2X55Y9E / bryostatin 1; 5J49Q6B70F / Vincristine
  • [Number-of-references] 38
  •  go-up   go-down


30. Deeken JF, Pantanowitz L, Dezube BJ: Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol; 2009 Sep;21(5):445-54
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.
  • PURPOSE OF REVIEW: Highly active antiretroviral therapy has led to a dramatic improvement in the prognosis of patients diagnosed with HIV and AIDS.
  • This includes a significant decline in the rates of AIDS-related cancers, including Kaposi's sarcoma and non-Hodgkin's lymphoma.
  • Unfortunately, rates of non-AIDS-defining cancers are on the rise, and now exceed the rates of AIDS-related cancers in patients with HIV.
  • Treating non-AIDS-defining cancers in patients who are on highly active antiretroviral therapy is an open and complicated clinical question.
  • RECENT FINDINGS: Newer targeted therapies are now available to treat cancers which were historically refractory to traditional cytotoxic chemotherapy.
  • We conclude with considerations on how to use these new agents to treat non-AIDS-defining cancers, and discuss a future research agenda to better understand and predict potential highly active antiretroviral therapy-targeted therapy interactions.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Pharmacol. 2008 Jan;64(1):31-41 [18000659.001]
  • [Cites] J Clin Pharmacol. 2008 Feb;48(2):209-14 [18077730.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:27-37 [18333863.001]
  • [Cites] Br J Cancer. 2008 Jun 3;98(11):1797-802 [18458675.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] Drug Metab Dispos. 2008 Sep;36(9):1828-39 [18556438.001]
  • [Cites] J Clin Pharmacol. 2008 Sep;48(9):1032-40 [18728241.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2008 Jun;30(5):383-408 [18806898.001]
  • [Cites] Top HIV Med. 2008 Oct-Nov;16(4):117-21 [18838745.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Sep;6 Suppl 5:S1-20; quiz S21-2 [18926092.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88 [18985183.001]
  • [Cites] Clin Ther. 2008 Nov;30(11):1956-75 [19108785.001]
  • [Cites] Clin Genitourin Cancer. 2009 Jan;7(1):24-7 [19213664.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] Eur J Cancer. 2009 Mar;45(4):579-87 [19101137.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2008 Dec;30(10):761-82 [19271026.001]
  • [Cites] Br J Clin Pharmacol. 2009 Apr;67(4):421-6 [19371315.001]
  • [Cites] Clin Pharmacokinet. 2009;48(3):199-209 [19385713.001]
  • [Cites] Drug Metab Dispos. 2009 Jun;37(6):1242-50 [19282395.001]
  • [Cites] Drug Metab Dispos. 1999 Dec;27(12):1488-95 [10570031.001]
  • [Cites] Drug Metab Dispos. 2001 Feb;29(2):100-2 [11159797.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2009 Mar;31(2):107-46 [19455266.001]
  • [Cites] Clin Pharmacol Ther. 1990 May;47(5):647-54 [2111751.001]
  • [Cites] Drug Metab Dispos. 1990 May-Jun;18(3):369-72 [1974201.001]
  • [Cites] AIDS. 1992 Dec;6(12):1471-5 [1283519.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Apr;277(1):423-31 [8613951.001]
  • [Cites] Drug Metab Dispos. 1997 Feb;25(2):256-66 [9029057.001]
  • [Cites] J Clin Pharmacol. 1998 Feb;38(2):106-11 [9549640.001]
  • [Cites] Drug Metab Dispos. 1998 Jun;26(6):552-61 [9616191.001]
  • [Cites] J Pharm Sci. 1998 Jul;87(7):803-7 [9649346.001]
  • [Cites] Drug Metab Dispos. 1998 Jul;26(7):609-16 [9660842.001]
  • [Cites] Drug Metab Dispos. 1999 Jan;27(1):86-91 [9884314.001]
  • [Cites] Drug Metab Dispos. 1999 Aug;27(8):902-8 [10421617.001]
  • [Cites] J Med Chem. 2004 Dec 30;47(27):6658-61 [15615512.001]
  • [Cites] Clin Pharmacokinet. 2005;44(2):111-45 [15656694.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Clin Pharmacokinet. 2005;44(9):879-94 [16122278.001]
  • [Cites] Clin Colorectal Cancer. 2005 Sep;5(3):188-96 [16197622.001]
  • [Cites] Drug Metab Dispos. 2005 Nov;33(11):1723-8 [16103134.001]
  • [Cites] Drug Metab Dispos. 2005 Nov;33(11):1729-39 [16118329.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):144-51 [16397036.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85 [16433896.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 May;57(5):685-92 [16133532.001]
  • [Cites] Drug Metab Dispos. 2006 Mar;34(3):420-6 [16381666.001]
  • [Cites] Drug Metab Dispos. 2006 Apr;34(4):702-8 [16443666.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2531-41 [16775234.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] JAMA. 2006 Aug 16;296(7):827-43 [16905788.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Nov;50(11):3801-8 [16940065.001]
  • [Cites] Neuro Endocrinol Lett. 2006 Dec;27 Suppl 2:27-30 [17159773.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2733-43 [17192538.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(1):55-63 [17095207.001]
  • [Cites] Drug Metab Dispos. 2007 Apr;35(4):602-6 [17267620.001]
  • [Cites] Clin Pharmacol Ther. 2002 Jul;72(1):1-9 [12151999.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Curr Pharm Des. 2002;8(25):2255-7 [12369853.001]
  • [Cites] Chem Biol Interact. 2002 Nov 10;142(1-2):135-54 [12399160.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):327-37 [12538485.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):471-8 [12748309.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4009-16 [12873999.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Br J Cancer. 2003 Nov 17;89(10):1855-9 [14612892.001]
  • [Cites] Int J Clin Pharmacol Ther. 2003 Dec;41(12):618-9 [14692719.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1034-40 [15247556.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Oct;54(4):290-4 [15138710.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3207-13 [17185463.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2684-91 [17473200.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Pharmacotherapy. 2007 Jun;27(6):888-909 [17542771.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3731-7 [17575239.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4849-57 [17699864.001]
  • [Cites] Drug Metab Dispos. 2007 Sep;35(9):1554-63 [17540708.001]
  • [Cites] Drug Metab Dispos. 2007 Sep;35(9):1657-63 [17591678.001]
  • [Cites] J Clin Pharmacol. 2007 Nov;47(11):1430-9 [17913896.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3540-6 [17715389.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7394-400 [18094422.001]
  • (PMID = 19606034.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA121947
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 118
  • [Other-IDs] NLM/ NIHMS382143; NLM/ PMC3377583
  •  go-up   go-down


31. Nguyen ML, Farrell KJ, Gunthel CJ: Non-AIDS-Defining Malignancies in Patients with HIV in the HAART Era. Curr Infect Dis Rep; 2010 Jan;12(1):46-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-Defining Malignancies in Patients with HIV in the HAART Era.
  • The introduction of highly active antiretroviral therapy (HAART) has drastically changed the scope and spectrum of diseases associated with HIV, shifting from AIDS-related to non-AIDS-related diseases.
  • Studies linking HIV/AIDS databases to cancer registries have shown a dramatic decrease in AIDS-related malignancies and a steady increase in non-AIDS-defining malignancies (NADM).
  • Meta-analysis of published studies show an increase in NADM over the general population, mostly among infection-related cancers such as anal cancer, Hodgkin lymphoma, and liver cancer.
  • Among the non-infection-related cancers, lung and skin cancers predominate.
  • As HIV-infected individuals survive longer, better screening strategies are needed to detect cancer earlier, and prospective data are needed to assess the impact of HAART on cancer outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Immun Ageing. 2008 Sep 24;5:11 [18816370.001]
  • [Cites] Arch Intern Med. 2009 Jun 22;169(12):1130-8 [19546414.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):3-10 [19339934.001]
  • [Cites] Curr Opin Infect Dis. 2009 Feb;22(1):7-10 [19532075.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Transplant Proc. 2008 Jul-Aug;40(6):1965-71 [18675102.001]
  • [Cites] AIDS. 2009 May 15;23(8):875-85 [19349851.001]
  • [Cites] AIDS. 2008 Oct 18;22(16):2135-41 [18832877.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):861-8 [15213571.001]
  • [Cites] AIDS. 2004 Nov 19;18(17):2285-93 [15577541.001]
  • [Cites] Clin Infect Dis. 2009 Oct 1;49(7):1109-16 [19705973.001]
  • [Cites] AIDS. 2008 Apr 23;22(7):841-8 [18427202.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Sep;43(1):47-55 [16936558.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):305-9 [19412116.001]
  • [Cites] AIDS. 2003 Jan 3;17(1):81-7 [12478072.001]
  • [Cites] Exp Gerontol. 2007 May;42(5):432-7 [17307327.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] AIDS Educ Prev. 2009 Jun;21(3 Suppl):3-13 [19537950.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):506-12 [11330577.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] AIDS. 2009 Nov 13;23(17):2337-45 [19741479.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):6-7 [17617251.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2590-3 [18224690.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1957-63 [17721103.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Oncol Rep. 2007 May;17(5):1121-6 [17390054.001]
  • [Cites] Arch Intern Med. 2008 Nov 24;168(21):2326-32; discussion 2332 [19029496.001]
  • [Cites] Lung Cancer. 2006 Jan;51(1):1-11 [16300854.001]
  • [Cites] Curr Infect Dis Rep. 2009 Sep;11(5):407-13 [19698285.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):527-37 [17692986.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Leuk Lymphoma. 2007 Oct;48(10):2058-9 [17917974.001]
  • [Cites] Lung Cancer. 2009 Sep;65(3):345-50 [19135758.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]
  • (PMID = 21308498.001).
  • [ISSN] 1534-3146
  • [Journal-full-title] Current infectious disease reports
  • [ISO-abbreviation] Curr Infect Dis Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D: AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol; 2008 Oct 10;26(29):4834-42
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: state of the art and therapeutic challenges.
  • Despite the impact of combination antiretroviral therapy (cART) on HIV-related mortality, malignancy remains an important cause of death in the current era.
  • Although the advent of cART has resulted in reductions in the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma, non-AIDS-defining malignancies present an increased risk for HIV-infected patients, characterized by some common clinical features, generally with a more aggressive behavior and a more advanced disease at diagnosis, which is responsible for poorer patient outcomes.
  • Specific therapeutic recommendations are lacking for these new nonopportunistic malignancies, such as Hodgkin's lymphoma, anal cancer, lung cancer, hepatocarcinoma, and many others.
  • Special considerations of these AIDS-related and non-AIDS-related malignancies and their clinical and therapeutic aspects constitute the subject of this review.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591544.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


33. Orem J, Otieno MW, Banura C, Katongole-Mbidde E, Johnson JL, Ayers L, Ghannoum M, Fu P, Feigal EG, Black J, Whalen C, Lederman M, Remick SC: Capacity building for the clinical investigation of AIDS malignancy in East Africa. Cancer Detect Prev; 2005;29(2):133-45
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capacity building for the clinical investigation of AIDS malignancy in East Africa.
  • PURPOSE: To build capacity in the resource-poor setting to support the clinical investigation and treatment of AIDS-related malignancies in a region of the world hardest hit by the AIDS pandemic.
  • METHODS: An initial MEDLINE database search for international collaborative partnerships dedicated to AIDS malignancies in developing countries failed to identify any leads.
  • Building on the formal Uganda-Case Western Reserve University (Case) Research Collaboration dating back to 1987, established NIH-supported centers of research excellence at Case, and expanding activities in Kenya, scientific and training initiatives, research capital amongst our institutions are emerging to sustain a international research enterprise focused on AIDS and other viral-related malignancies.
  • An oral chemotherapy feasibility trial in AIDS lymphoma is near completion; a second lymphoma trial of byrostatin and vincristine is anticipated and a feasibility trial of indinavir for endemic Kaposi's sarcoma is planned.
  • CONCLUSIONS: In the absence of published reports of evolving international partnerships dedicated to AIDS malignancy in resource constrained settings, we feel it important for such progress on similar or related international collaborative pursuits to be published.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15829373.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. Rao D, Debb S, Blitz D, Choi SW, Cella D: Racial/Ethnic differences in the health-related quality of life of cancer patients. J Pain Symptom Manage; 2008 Nov;36(5):488-96

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial/Ethnic differences in the health-related quality of life of cancer patients.
  • Previous research has suggested that, when compared to European Americans (EAs), African Americans (AAs) are at higher risk of metastatic disease at time of cancer diagnosis, and a higher risk of shorter survival.
  • Although AA patients have reported worse physical health than EA patients, studies have rarely addressed whether racial/ethnic disparities exist on the social, emotional, and functional aspects of health-related quality of life.
  • Five hundred and two AA and 396 EA patients with AIDS-related malignancies or breast, colon, head/neck, and lung cancers seeking treatment within the contiguous United States and Puerto Rico participated in the present study.
  • Responses on the Functional Assessment of Cancer Therapy-General were analyzed for possible racial/ethnic disparities using multivariable regression models and item response theory modeling to detect differential item functioning.
  • Differential item functioning was found in six items of the Functional Assessment of Cancer Therapy-General, indicating that AA and EA participants had different probabilities of responding to these items.
  • Compared to EAs at the same level of health-related quality of life, AAs reported more severe symptomatology on items that reflected malaise and ability to work, and less severe symptomatology on items that reflected fatigue, treatment side effects, and outlook on life.
  • Some items appear to be responded to differently by AAs and EAs, suggesting it is important to consider race/ethnicity when evaluating responses to questions about health-related quality of life.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Health Serv Res. 2000 Feb;34(6):1273-302 [10654830.001]
  • [Cites] Med Care. 2008 Apr;46(4):423-31 [18362823.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):219-25 [11158191.001]
  • [Cites] J Natl Cancer Inst. 2001 Mar 7;93(5):388-95 [11238701.001]
  • [Cites] Cancer. 2001 May 1;91(9):1834-43 [11335911.001]
  • [Cites] J Urol. 2001 Dec;166(6):2281-5 [11696752.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1451-9 [11745222.001]
  • [Cites] Cultur Divers Ethnic Minor Psychol. 2002 Nov;8(4):366-77 [12416322.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):311-7 [12491494.001]
  • [Cites] Arch Phys Med Rehabil. 2003 Apr;84(4 Suppl 2):S35-42 [12692770.001]
  • [Cites] Pain Med. 2003 Sep;4(3):277-94 [12974827.001]
  • [Cites] Psychooncology. 2004 Jun;13(6):408-28 [15188447.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):570-9 [8445433.001]
  • [Cites] JAMA. 1995 Jan 4;273(1):59-65 [7996652.001]
  • [Cites] J Health Soc Behav. 1995 Mar;36(1):1-10 [7738325.001]
  • [Cites] Int J Health Serv. 1996;26(3):483-505 [8840198.001]
  • [Cites] Cancer. 1997 Oct 1;80(7):1261-6 [9317177.001]
  • [Cites] Med Care. 1998 Sep;36(9):1407-18 [9749663.001]
  • [Cites] Urology. 2005 Jan;65(1):101-8 [15667873.001]
  • [Cites] J Health Care Poor Underserved. 2005 May;16(2):375-90 [15937399.001]
  • [Cites] Urology. 2006 May;67(5):1022-7 [16698362.001]
  • [Cites] Med Care. 2006 Nov;44(11 Suppl 3):S3-4 [17060831.001]
  • [Cites] Cultur Divers Ethnic Minor Psychol. 2007 Jan;13(1):64-71 [17227178.001]
  • [Cites] Cancer. 2000 Mar 1;88(5 Suppl):1217-23 [10705358.001]
  • (PMID = 18504096.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01-CA61679; United States / NIAMS NIH HHS / AR / U01 AR052177; United States / NIAMS NIH HHS / AR / AR052177-04; United States / NIAMS NIH HHS / AR / U01 AR052177-04; United States / NCI NIH HHS / CA / R01 CA061679
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS78122; NLM/ PMC2596636
  •  go-up   go-down


35. Bower M, Palmieri C, Dhillon T: AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis; 2006 Feb;19(1):14-9
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy.
  • PURPOSE OF REVIEW: Three cancers in people with HIV denote an AIDS diagnosis: Kaposi's sarcoma, high-grade B-cell non-Hodgkin's lymphoma and invasive cervical cancer.
  • In addition a number of other cancers occur at increased frequency in this population group but are not AIDS-defining illnesses.
  • This review discusses the impact of highly active antiretroviral therapy on the epidemiology and outcome of AIDS-defining cancers.
  • In contrast, highly active antiretroviral therapy has had little impact on the incidence of human papilloma virus-associated tumours (cervical and anal cancer) in people with HIV, although it may improve survival by reducing opportunistic infection deaths.
  • As people with HIV live longer with highly active antiretroviral therapy, an increased incidence of other non AIDS-defining cancers that have no known association with oncogenic infections is becoming apparent.
  • SUMMARY: For those with access to highly active antiretroviral therapy, the good news from the AIDS-defining cancers - particularly Kaposi's sarcoma and non-Hodgkin's lymphoma - may be balanced by the increasing numbers of non AIDS-defining cancers.
  • [MeSH-minor] Female. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374212.001).
  • [ISSN] 0951-7375
  • [Journal-full-title] Current opinion in infectious diseases
  • [ISO-abbreviation] Curr. Opin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


36. Stebbing J, Powles T, Mandalia S, Nelson M, Gazzard B, Bower M: Use of antidepressants and risk of cancer in individuals infected with HIV. J Clin Oncol; 2008 May 10;26(14):2305-10
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of antidepressants and risk of cancer in individuals infected with HIV.
  • PURPOSE: Preclinical and cohort studies suggest that certain antidepressants are associated with a predisposition to cancer whereas others decrease the risk.
  • We aimed to assess whether different classes of antidepressants were associated with changes in cancer incidence in a population of HIV-1 infected individuals, based on duration of exposure.
  • METHODS: Antidepressant exposure was measured from date of first prescription of the antidepressant until the date of last follow-up or cancer diagnosis.
  • Univariate and multivariate analyses were performed to establish the risk of AIDS-related cancers and non-AIDS-related cancers according to whether patients were receiving selective serotonin reuptake inhibitors, tricyclic antidepressants, or other medicines for depression.
  • A total of 1,607 (15%) individuals were diagnosed with cancer.
  • There were no significant associations between any class of antidepressant and any type of cancer (P = .19), in either the pre-HAART or HAART era (P = .23), and use of serotonin reuptake inhibitors did not alter the risk of Burkitt lymphoma.
  • CONCLUSION: Antidepressants, irrespective of their class, do not affect cancer risk in HIV-infected individuals.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18467722.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Antidepressive Agents, Tricyclic; 0 / Serotonin Uptake Inhibitors
  •  go-up   go-down


37. Cadogan M, Dalgleish AG: HIV induced AIDS and related cancers: chronic immune activation and future therapeutic strategies. Adv Cancer Res; 2008;101:349-95
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV induced AIDS and related cancers: chronic immune activation and future therapeutic strategies.
  • Chronic generalized immune activation represents one of the most critical features determining progression to AIDS.
  • This may result in the manifestation of malignancy, with lymphoma and Karposi's sarcoma being the first to be recognised.
  • Despite a lifecycle adapted to the host and possessing a plethora of survival strategies, HIV promotes disease progression in a manner that is consistently associated with the HLA repertoire suggesting pathogenic features relating to immunological incompatibility may be at the root of disease.
  • Here we review the influence of immune activation on progression to AIDS with particular reference to molecular mimicry and autoimmune phenomenon and highlight the therapeutic potential of non-neutralizing antibodies and strategies designed to diffuse immune activation.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / etiology. Alleles. Amino Acid Sequence. Animals. Disease Progression. Disease Susceptibility. HLA Antigens / chemistry. Humans. Immune System. Molecular Sequence Data. Sequence Homology, Amino Acid. Treatment Outcome

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055948.001).
  • [ISSN] 0065-230X
  • [Journal-full-title] Advances in cancer research
  • [ISO-abbreviation] Adv. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  • [Number-of-references] 350
  •  go-up   go-down


38. Tserenpuntsag B, Kołacińska A, Jabłonowska E: [AIDS associated cancers in the era of highly active antiretroviral therapy (HAART)]. Przegl Epidemiol; 2007;61(3):529-34
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS associated cancers in the era of highly active antiretroviral therapy (HAART)].
  • [Transliterated title] Nowotwory zwiazane z AIDS w erze skojarzonego leczenia antyretrowirusowego (HAART).
  • HIV infected subjects are at increased risk of developing cancer and the risk seems to be directly associated with the level of immunodeficiency.
  • Kaposi's sarcoma, Non-Hodgkin's lymphoma (ARL) and invasive cervical cancer are the most common AIDS-defining malignancies.
  • It significantly reduced the incidence of AIDS associated events and deaths and even changed treatment regimens ofAIDS associated cancers.
  • With the immune restoration afforded by HAART, patients better responded to cancer treatment.
  • HAART allows the use of standard-dose chemotherapies for NON-Hodgkin lymphoma in HIV infected pacients and same treatment regimen for invasive cervical cancer in infected patients as non-infected patients.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / virology. Sarcoma, Kaposi / virology. Uterine Cervical Neoplasms / virology


39. Ayers LW, Silver S, McGrath MS, Orenstein JM: The AIDS and Cancer Specimen Resource: role in HIV/AIDS scientific discovery. Infect Agent Cancer; 2007;2:7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The AIDS and Cancer Specimen Resource: role in HIV/AIDS scientific discovery.
  • The AIDS Cancer and Specimen Resource (ACSR) supports scientific discovery in the area of HIV/AIDS-associated malignancies.
  • The ACSR was established as a cooperative agreement between the NCI (Office of the Director, Division of Cancer Treatment and Diagnosis) and regional consortia, University of California, San Francisco (West Coast), George Washington University (East Coast) and Ohio State University (Mid-Region) to collect, preserve and disperse HIV-related tissues and biologic fluids and controls along with clinical data to qualified investigators.
  • ACSR also provides tissue microarrays of, e.g., Kaposi's sarcoma and non-Hodgkin's lymphoma, for biomarker assays and has developed collaborations with other groups that provide access to additional AIDS-related malignancy specimens.
  • The ACSR promotes the scientific exploration of the relationship between HIV/AIDS and malignancy by participation at national and international scientific meetings, contact with investigators who have productive research in this area and identifying, collecting, preserving, enhancing, and dispersing HIV/AIDS-related malignancy specimens to funded, approved researchers at no fee.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Res. 2003 Oct 15;60(1):108-18 [14522412.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2004;50 Online Pub:OL581-9 [15555424.001]
  • [Cites] Pediatr Infect Dis J. 2005 Mar;24(3):237-42 [15750460.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] BMC Med Inform Decis Mak. 2005;5:12 [15871741.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1373-80 [15923317.001]
  • [Cites] Science. 2005 Jun 10;308(5728):1582-3 [15947174.001]
  • [Cites] BMC Med Inform Decis Mak. 2005;5:25 [16086837.001]
  • [Cites] J Virol. 2005 Sep;79(17):11343-52 [16103186.001]
  • [Cites] Int J Hematol. 2006 Jul;84(1):3-11 [16867895.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):696-701 [10655369.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1599-601 [10942415.001]
  • [Cites] Nat Med. 2001 Jan;7(1):73-9 [11135619.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):733-41 [12428794.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1961-71 [12466110.001]
  • [Cites] BMC Med Inform Decis Mak. 2003 May 23;3:5 [12769826.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20 [12843741.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4620-9 [8977254.001]
  • [Cites] AIDS Res Hum Retroviruses. 1997 Jan 20;13(2):135-49 [9007199.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • (PMID = 17335575.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA066531
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1851770
  •  go-up   go-down


40. Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal E, Jougla E, Cacoub P, Salmon D, Chêne G, Morlat P, Agence Nationale de Recherches sur le Sida et les Hépatites Virales EN19 Mortalité Study Group, Mortavic Study Group: Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis; 2009 Mar 1;48(5):633-9
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey.
  • BACKGROUND: The goal of the current study was to describe the distribution and characteristics of malignancy related deaths among human immunodeficiency virus (HIV)-infected patients with use of data obtained from a national survey conducted in France in 2005 and to compare with results obtained from a similar survey conducted in 2000.
  • RESULTS: Among the 1042 deaths reported in 2005 (964 were reported in 2000), 344 were cancer related (34%), which represented a significant increase from 2000 (29% of deaths were cancer related) (P=.02); 134 of the cancer-related deaths were AIDS related and 210 were not AIDS related.
  • Among the cancer-related causes of death, the proportion of hepatitis-related cancers (6% in 2000 vs. 11% in 2005) and non-AIDS/hepatitis-related cancers (38% in 2000 vs 50% in 2005) significantly increased from 2000 to 2005 (P=.03 and P=.01, respectively), compared with the proportion of cancer that was AIDS related and adjusting for age and sex.
  • Among cases involving AIDS, the proportion of non-Hodgkin lymphoma-associated deaths did not change statistically significantly between 2000 and 2005 (11% and 10% of deaths, respectively).
  • CONCLUSIONS: In this study, an increasing proportion of lethal non-AIDS-related cancers was demonstrated from 2000 to 2005; meanwhile, the proportion of lethal AIDS-related cancers remained stable among HIV-infected patients.
  • Thus, cancer prophylaxis, early diagnosis, and improved management should be included in the routine long-term follow-up of HIV-infected patients.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Infect Dis. 2009 Aug 1;49(3):481-2 [19586399.001]
  • [CommentIn] Clin Infect Dis. 2009 Mar 1;48(5):640-1 [19202628.001]
  • (PMID = 19202627.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Chêne G; Costagliola D; Jougla E; May T; Morlat P; Salmon D; Cacoub P; Rosenthal E; Bonnet F; Burty C; Lewden C; François M; Boileau J; Zouari H; Tourteau F; Bursacchi P; Delfraissy JF; Semaille C; Redecker S; Imbert Y; Rispal P; Allegre T; Riou J; Marquant M; Undreiner P; Abino J; Barel P; Greziller; Gosse; Lagier A; Bastide D; Schmit J; Decaux N; Chennebault J; Fialaire P; Abgueguen P; Loison J; Gaillat J; Legrand E; Dor J; Quinsat D; Lerousseau L; Chavaillon; Toquet-Maillet E; Sutton L; Genet P; Salord J; Raison G; Dubois D; Lierman Y; Bervar J; Castan B; Malbec D; Delassus J; Bakir R; Lepeu G; Pichancourt G; Theodourou-Touchais A; De La Blanchardiere OA; Evon P; Aubry Y; Giffo B; Bonnal F; Labarrere S; Amanieu M; Valet D; Faller J; Eglinger P; Duchene F; Humbert P; Dupond J; Estavoyer J; Hoen B; Roche C; Chirouze C; Faucher J; Oziol E; Saad A; Cabrol M; Gateau P; Seiberras S; Vidal C; Mazari A; Bentata M; Honore P; Bouchaud O; Bessin C; Jeantils V; Tassi S; Fain O; Dupon M; Morlat P; Beylot J; Lacoste D; Bonarek M; Bernard N; Bonnet F; Ragnaud J; Longy-Boursier M; Mercie P; Series C; Portal B; Terrier F; Rouveix E; Olivier C; Vaillant J; Moulias S; Hanslik T; Granier P; Colucci T; Mornet M; Aaron L; Guimard Y; Agbodjan J; Julien J; Fabre M; Garre M; Gouerou; Savary O; Nousbaum J; Granier H; Brousse P; Verdon R; Feret P; Guivarch; Sire S; Simonet P; Tempesta S; Vialatte B; Prudhomme L; Djossou F; Bichat S; Nacher M; Couppie P; Dellinger; Picard J; Sabbagh; Rogeaux O; Penalba C; Aubert C; Alba C; Galanaud P; Delavalle A; Boue F; Defuentes G; Pik J; Laurichesse H; Beytout J; Cormerais L; Fantin B; Uludag A; Mantz J; Cohen J; Kohser F; Plaisance N; Blaison G; Martinot M; Minozzi C; Ferreira C; Zeng F; Domart Y; Merrien D; Zylberait D; Devidas A; Turpauld I; Chevojon P; Bardet M; Jacquemard P; Sobel A; Jung C; Dumont C; Chousterman M; Housset B; Bassinet L; Schortgen F; Loste P; Antoniotti O; Nehme E; Granet P; Brunello; Portier H; Grappin M; Buisson M; Duong M; Braconnier C; Waldner-Combernoux A; Laine J; Brousse A; Cardon G; Visticot F; Vella M; Bonnevie F; Vanrenterghem; Soupison T; Gruat N; Roche J; Sicot; Saraux J; Lepretre A; El Hajj L; Frossard; Brung M; Lefebvre; Beguinot I; Schuhmacher H; Hirsch J; Reumont G; Saad; Galan; Estebe; Cabie A; Abel S; Quist D; Counillon E; Armero R; Del Giudice P; Gamblin V; Bouchard I; De Truchis P; Berthe H; Leclercq P; Brambilla C; Gineste E; Sarrot-Reynauld F; Jenny; Class J; Raynaud-Simon A; Alvarez F; Perre P; Aubry O; Suaud I; Courbes I; Batejat B; Dupont A; Lagarde P; David-Ouaknine F; Le Moigne E; Caumont B; Robin M; Hoel J; Doll J; Colardelle P; Roussin-Bretagne S; Greder A; Belan; Bedos J; Bruneel F; Thibous F; Lemeunier; Delfraissy J; Goujard C; Rannou M; Wind P; Monange B; Lamblin C; Cochonat K; Balquet M; De Ribes DC; Force G; Ceccaldi J; Marcos J; Hammou Y; Codaccioni X; Weinbreck P; Genet C; Debette-Gratien M; Geffray L; Le Mercier Y; Follet; Duvert B; Lacroix; Arnaud A; Selles Y; Levasseur F; Touraine J; Jeanblanc F; Trepo C; Benmakhlouf N; Lebouche B; Peyramond D; Boibieux A; Chidiac C; Delorme C; Carbonnel E; Baty V; Kisterman J; Roubert X; Granier F; Tremolières F; Billy C; Perronne V; Testaud J; Gastaut J; Drogoul M; Fabre G; Moreau J; Vandergheynst E; Bourliere M; Ruiz J; Philibert P; Gamby T; Petit N; Simon F; Fontaneau; Meissonnier P; Bayada J; Christian B; Armand A; Galzin M; Dumas D; De Witte S; Jobard J; Poncet A; Caillet B; Reynes J; De Boever CM; Siffert M; Bourgeois A; Villadoro A; Tramoni C; Faucherre V; Larrey D; Jonquet O; Landreau; Andre M; Winter C; Roge C; Beck-Wirth G; Drenou B; Benomar M; Ruel M; Chemlal K; Raffi F; Morineau-Le Houssine P; Le Bavec CG; Lemesre F; Masson B; Loison F; Razafimahery M; De Lacour JL; Dellamonica P; Mondain-Miton V; Cua E; Oran N; Valerio L; Rosenthal E; Fuzibet J; Tran A; Brocker P; Barrelier P; Vincent D; Mauboussin J; Barbuat C; Rouanet I; Jourdan N; Sotto A; Del Bucchia F; Jourdan J; Lapine M; Capdevielle P; Lacassin-Beller F; Droetto F; Diab G; Grihon F; Arsac P; Hocqueloux L; Levasseur M; Fourdilis M; Jarno P; Derouineau J; Morel P; Timsit F; Compagnucci A; Oksenhendler E; Gerard L; Delgado J; Sereni D; Lascoux-Combe C; Viard J; Dupont B; Maignan A; Bergmann J; Sellier P; Magnier J; Pialoux G; Godard V; Goetschel A; Lebrette M; Weiss L; Tisne-Dessus D; Leport C; Ecobichon J; Colasante U; Guillevin L; Salmon-Ceron D; Pietri M; Brunet A; Silbermann B; Blanche P; Schoen H; Valantin M; Hausfater P; Martinez V; Herson S; Simon A; Brancon C; Girard P; Begle A; Raguin G; Lupin C; Molina J; Ponscarme D; Garrait V; Cabotin P; Janier M; Spindler E; Yeni P; Gerbe J; Cabane J; Ziza J; Aerts J; Carlet J; Gilquin J; Auperin I; Misset B; Crof A; Piette J; Cacoub P; Turpin G; Varet B; Dupin N; Le Jeunne C; Aslangul E; Pol S; Poynard T; Lebray P; Carbonell N; Benlian P; Goujon M; Dhainaut J; Charpentier J; Andrieu J; Brunel M; Landgraf N; Bary M; Pouyanne; Meraud J; Riviere C; Aumaître H; Saada M; Cros H; Pellegrin J; Adjeoda R; Durieu I; Rousset H; Vital-Durand D; Lamaury I; Sow M; Hillion D; Masson H; Becq-Giraudon B; Le Moal G; Silvain C; Danne O; Blum L; Larzul J; Perfezou P; Rouger C; Novella J; Michelet C; Tattevin P; Arvieux C; Souala F; Delmont-Hanry M; Guyader D; Gandemer V; Camus C; Taverson; Lutz M; Climas M; Wemeau J; Gueit I; Suel P; Caron F; Mechali D; Khuong-Josses M; Etienne Y; Lucht F; Fresard A; Ronat V; Vergnon; Garcier; Deluca J; Randrianjohany A; Monnot H; Poubeau P; Andre H; Beuscart C; Aubry M; Hurbin E; Debord T; Rapp C; Bissuel F; Walter V; Ferret J; Bonnefoy M; Riche A; Marot J; Michau C; Bonnin E; Pasdeloup T; Chaby G; Grilliat E; Wurtz E; Loth F; Kitschke B; Line D; Gaud C; Sautron C; Cathebras P; Welker Y; Sandron D; Lang J; Fischer P; Pasquali J; Lalanne H; Chartier C; Berlin C; Andres E; Christmann D; Hansmann Y; Fraisse P; Bletry O; Zucman D; Majerholc C; Stern M; Couderc L; Petitou J; Truchetet F; Pouaha J; Romand P; Lafeuillade A; Lambry V; Bernard P; Adoue D; Duffaut M; Marchou B; Garipuy D; Cuzin L; Marchou B; Garipuy D; Cuzin L; Uzan M; Vinel J; Metivier S; Didier A; Rouquet R; Mouton Y; Yazdanpanah Y; Marysse F; Guery B; Faure K; Besnier J; Le Bret P; Nau P; Sigogneau H; Bressieux J; Libbrecht E; Rezzouk L; Collignon A; Ponceau B; Kyndt X; Vermersch-Langlin A; May T; Burty C; Lederlin P; Poinsignon Y; Creusat C; Richard C; Merle C; Essayan A; Vittecoq D; Bolliot C; Quignard; Patey O; Dellion S; Chossat I
  •  go-up   go-down


41. Nunnari G, Smith JA, Daniel R: HIV-1 Tat and AIDS-associated cancer: targeting the cellular anti-cancer barrier? J Exp Clin Cancer Res; 2008 May 15;27:3
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-1 Tat and AIDS-associated cancer: targeting the cellular anti-cancer barrier?
  • The acquired immunodeficiency syndrome (AIDS) is accompanied by a significant increase in the incidence of neoplasms.
  • Cancer in general is closely linked to genomic instability and DNA repair mechanisms.
  • The latter maintains genomic stability and serves as a cellular anti-cancer barrier.
  • Defects in DNA repair pathway are associated with carcinogenesis.
  • We propose that the Tat-induced DNA repair deficiencies may play a significant role in the development of AIDS-associated cancer.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2005 Apr 22;308(5721):551-4 [15790808.001]
  • [Cites] Cell Cycle. 2005 Mar;4(3):359-62 [15684609.001]
  • [Cites] EMBO J. 2005 Jul 20;24(14):2634-45 [16001085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13182-7 [16141325.001]
  • [Cites] Front Biosci. 2006;11:1958-76 [16368571.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):37-45 [16327781.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):91-9 [16341205.001]
  • [Cites] J Exp Med. 2006 Feb 20;203(2):297-303 [16461339.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):842-50 [16751065.001]
  • [Cites] Mol Cell. 2006 Dec 28;24(6):827-39 [17189186.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):993-1002 [16909103.001]
  • [Cites] Curr HIV Res. 2007 Jul;5(4):403-9 [17627503.001]
  • [Cites] Nature. 2007 Aug 30;448(7157):1063-7 [17728759.001]
  • [Cites] Nature. 1990 May 3;345(6270):84-6 [2184372.001]
  • [Cites] J Virol. 1993 Jan;67(1):277-87 [8416373.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5613-7 [8516308.001]
  • [Cites] Am J Gastroenterol. 1994 Feb;89(2):254-6 [8304313.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6904-8 [8041718.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]
  • [Cites] Nature. 1995 Jun 8;375(6531):497-500 [7539892.001]
  • [Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]
  • [Cites] Virology. 1996 Feb 15;216(2):357-66 [8607265.001]
  • [Cites] Cell. 1996 Aug 9;86(3):379-89 [8756720.001]
  • [Cites] J Virol. 1996 Nov;70(11):8151-4 [8892944.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1425-33 [9032269.001]
  • [Cites] J Infect Dis. 1997 Jul;176(1):84-93 [9207353.001]
  • [Cites] Nature. 1997 Jul 31;388(6641):492-5 [9242410.001]
  • [Cites] Curr Biol. 1997 Aug 1;7(8):588-98 [9259561.001]
  • [Cites] J Biol Chem. 1998 Jan 16;273(3):1623-8 [9430704.001]
  • [Cites] J Biol Chem. 1998 Mar 6;273(10):5858-68 [9488723.001]
  • [Cites] Mol Cell. 1998 Jun;1(7):969-79 [9651580.001]
  • [Cites] EMBO J. 1998 Sep 15;17(18):5497-508 [9736627.001]
  • [Cites] EMBO J. 1998 Nov 2;17(21):6412-25 [9799249.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3299-304 [10866324.001]
  • [Cites] Curr Biol. 2000 Jul 27-Aug 10;10(15):886-95 [10959836.001]
  • [Cites] Cell. 2000 Aug 18;102(4):463-73 [10966108.001]
  • [Cites] Adv Pharmacol. 2000;48:209-27 [10987092.001]
  • [Cites] Science. 1999 Nov 5;286(5442):1162-6 [10550055.001]
  • [Cites] Mutat Res. 1973 Oct;20(1):45-51 [4586554.001]
  • [Cites] Cancer. 1988 Aug 1;62(3):616-9 [3390798.001]
  • [Cites] Am J Clin Pathol. 1989 Apr;91(4):458-61 [2929501.001]
  • [Cites] Int J STD AIDS. 1999 Dec;10(12):795-802 [10639060.001]
  • [Cites] EMBO J. 2000 Apr 3;19(7):1703-10 [10747037.001]
  • [Cites] Nature. 2000 Apr 6;404(6778):613-7 [10766245.001]
  • [Cites] Nature. 2000 Apr 20;404(6780):897-900 [10786799.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):677-9 [10793096.001]
  • [Cites] Nat Genet. 2000 May;25(1):115-9 [10802669.001]
  • [Cites] Mol Cell Biol. 2000 Jun;20(11):3772-80 [10805721.001]
  • [Cites] Nature. 2000 May 25;405(6785):473-7 [10839544.001]
  • [Cites] Nature. 2000 May 25;405(6785):477-82 [10839545.001]
  • [Cites] Adv Pharmacol. 2000;48:229-50 [10987093.001]
  • [Cites] Nature. 2000 Nov 23;408(6811):433-9 [11100718.001]
  • [Cites] Genes Dev. 2000 Dec 1;14(23):2989-3002 [11114888.001]
  • [Cites] Curr Opin Genet Dev. 2001 Feb;11(1):71-7 [11163154.001]
  • [Cites] AIDS. 2001 Mar 9;15(4):433-40 [11242139.001]
  • [Cites] Am J Epidemiol. 2001 Sep 15;154(6):544-56 [11549560.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):42462-7 [11571274.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1713-6 [11721054.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):47759-62 [11673449.001]
  • [Cites] Mol Pathol. 2002 Feb;55(1):19-24 [11836442.001]
  • [Cites] EMBO J. 2002 Apr 2;21(7):1704-12 [11927554.001]
  • [Cites] Nat Cell Biol. 2002 Dec;4(12):993-7 [12447390.001]
  • [Cites] Nature. 2003 Jan 30;421(6922):499-506 [12556884.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):497-501 [12640452.001]
  • [Cites] Curr Drug Targets Infect Disord. 2003 Jun;3(2):115-28 [12769789.001]
  • [Cites] Science. 2003 Jun 6;300(5625):1542-8 [12791985.001]
  • [Cites] Angiogenesis. 2002;5(3):141-51 [12831055.001]
  • [Cites] Cell. 2003 Aug 8;114(3):371-83 [12914701.001]
  • [Cites] Am Surg. 2003 Nov;69(11):981-7 [14627261.001]
  • [Cites] Acta Biochim Pol. 2003;50(4):891-908 [14739985.001]
  • [Cites] Nature. 2004 Mar 25;428(6981):431-7 [15042092.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2664-71 [14755242.001]
  • [Cites] Mol Biol Cell. 2004 May;15(5):2347-60 [15020715.001]
  • [Cites] Curr Opin Genet Dev. 2004 Feb;14(1):11-6 [15108799.001]
  • [Cites] Curr Opin Genet Dev. 2004 Apr;14(2):147-54 [15196461.001]
  • [Cites] J Virol. 2004 Sep;78(17):9336-42 [15308728.001]
  • [Cites] Cancer Biol Ther. 2004 Jun;3(6):509-14 [15254414.001]
  • [Cites] Radiat Res. 1998 Nov;150(5 Suppl):S42-51 [9806608.001]
  • [Cites] Cell. 1998 Nov 25;95(5):583-6 [9845359.001]
  • [Cites] Cell. 1998 Nov 25;95(5):705-16 [9845372.001]
  • [Cites] Genes Cells. 1998 Dec;3(12):789-800 [10096020.001]
  • [Cites] Genes Dev. 1999 May 15;13(10):1276-88 [10346816.001]
  • [Cites] Biochemistry. 1999 Jul 6;38(27):8826-30 [10393559.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8324-6 [10411869.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1453-8 [10469745.001]
  • [Cites] J Cell Biol. 1999 Sep 6;146(5):905-16 [10477747.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4375-82 [10485486.001]
  • [Cites] Curr HIV Res. 2004 Oct;2(4):343-9 [15544455.001]
  • [Cites] Mol Cell. 2004 Dec 3;16(5):715-24 [15574327.001]
  • [Cites] Mutat Res. 2005 Jan 6;569(1-2):123-32 [15603757.001]
  • [Cites] Science. 2004 Dec 17;306(5704):2084-7 [15528408.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):949-61 [15592499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1877-82 [15671175.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2433; author reply 2433-4 [15800341.001]
  • [Cites] Nature. 2005 Mar 31;434(7033):605-11 [15758953.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):864-70 [15829956.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):907-13 [15829965.001]
  • (PMID = 18577246.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K01 CA098090; United States / NCI NIH HHS / CA / R01 CA125272; United States / NCI NIH HHS / CA / CA125272; United States / NCI NIH HHS / CA / CA98090
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / tat Gene Products, Human Immunodeficiency Virus
  • [Number-of-references] 99
  • [Other-IDs] NLM/ PMC2438332
  •  go-up   go-down


42. Ruff KR, Puetter A, Levy LS: Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6. BMC Cancer; 2007 Feb 26;7:35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6.
  • BACKGROUND: AIDS-related non-Hodgkin's lymphoma (AIDS-NHL) is the second most frequent cancer associated with AIDS, and is a frequent cause of death in HIV-infected individuals.
  • Experimental analysis of AIDS-NHL has been facilitated by the availability of an excellent animal model, i.e., simian Acquired Immunodeficiency Syndrome (SAIDS) in the rhesus macaque consequent to infection with simian immunodeficiency virus.
  • The authors concluded that TGF-beta acts as a negative growth regulator of the lymphoma-derived cell line and, potentially, as an inhibitory factor in the regulatory network of AIDS-related lymphomagenesis.
  • The present study was conducted to assess whether other SAIDS-NHL and AIDS-NHL cell lines are similarly sensitive to the growth inhibitory effects of TGF-beta, and to test the hypothesis that interleukin-6 (IL-6) may represent a counteracting positive influence in their growth regulation.
  • Intracellular flow cytometry was used to analyze the activation of signaling pathways and to examine the expression of anti-apoptotic proteins and distinguishing hallmarks of AIDS-NHL subclass.
  • By comparison, human AIDS-NHL cell lines differed in their responsiveness to TGF-beta1 and IL-6.
  • Analysis of a recently derived AIDS-NHL cell line, UMCL01-101, indicated that it represents immunoblastic AIDS-DLCBL.
  • CONCLUSION: These studies indicate that the sensitivity of immunoblastic AIDS- or SAIDS-DLBCL to TGF-beta1-mediated growth inhibition may be overcome through the stimulation of proliferative and anti-apoptotic signals by IL-6, particularly through the rapid activation of STAT3.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS Res Hum Retroviruses. 1999 Nov 1;15(16):1477-85 [10555111.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):23013-9 [10438468.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Jan 20;16(2):163-71 [10659055.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2468-73 [10851045.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2496-504 [10851048.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2548-56 [10851053.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):431-41 [10950370.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2500-10 [10946276.001]
  • [Cites] Leuk Lymphoma. 2000 Aug;38(5-6):481-8 [10953968.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4084-90 [11110677.001]
  • [Cites] FEBS Lett. 2001 Jan 19;488(3):179-84 [11163768.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):351-62 [11160159.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):709-23 [11297268.001]
  • [Cites] Oncogene. 2001 Feb 8;20(6):677-85 [11314001.001]
  • [Cites] Oncogene. 2001 May 3;20(20):2499-513 [11420660.001]
  • [Cites] AIDS Res Hum Retroviruses. 2001 May 20;17(8):745-51 [11429114.001]
  • [Cites] J Med Virol. 2001 Sep;65(1):114-20 [11505452.001]
  • [Cites] Oncogene. 2001 Sep 13;20(41):5799-809 [11593385.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] Blood. 2002 Jul 1;100(1):194-9 [12070027.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):316-26 [12538484.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):3867-72 [12553006.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):661-8 [12740915.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] Biochem J. 2003 Aug 15;374(Pt 1):1-20 [12773095.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1731-7 [12970772.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6639-45 [14528289.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 2003;149:1-38 [12687404.001]
  • [Cites] J Virol. 2004 Feb;78(4):1697-705 [14747535.001]
  • [Cites] Vet Pathol. 1988 Nov;25(6):456-67 [2850650.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):564-70 [10508495.001]
  • [Cites] AIDS Res Hum Retroviruses. 1999 Oct 10;15(15):1389-98 [10515154.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):10491-500 [15637055.001]
  • [Cites] Oncogene. 2005 Mar 24;24(13):2121-43 [15789036.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10153-63 [16478725.001]
  • [Cites] Blood. 1992 Jul 15;80(2):498-504 [1320956.001]
  • [Cites] Blood. 1994 Feb 15;83(4):1067-78 [8111047.001]
  • [Cites] Oncogene. 1995 Oct 19;11(8):1615-22 [7478586.001]
  • [Cites] J Interferon Cytokine Res. 1995 Mar;15(3):261-8 [7584673.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):40-3 [8548771.001]
  • [Cites] Virology. 1995 Dec 20;214(2):431-8 [8553544.001]
  • [Cites] Blood. 1996 Aug 1;88(3):809-16 [8704235.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]
  • [Cites] Immunity. 1996 Nov;5(5):449-60 [8934572.001]
  • [Cites] Blood. 1997 Feb 1;89(3):941-7 [9028325.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5877-81 [9159168.001]
  • [Cites] AIDS Res Hum Retroviruses. 1997 Dec 10;13(18):1589-96 [9430251.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):143-9 [9792301.001]
  • [Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]
  • [Cites] Br J Haematol. 1999 Nov;107(2):392-5 [10583232.001]
  • (PMID = 17324269.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA074731; United States / NCI NIH HHS / CA / R01 CA74731
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Interleukin-6; 0 / Transforming Growth Factor beta1
  • [Other-IDs] NLM/ PMC1810304
  •  go-up   go-down


43. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature; 2008 Jul 24;454(7203):436-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-related inflammation.
  • In some types of cancer, inflammatory conditions are present before a malignant change occurs.
  • Conversely, in other types of cancer, an oncogenic change induces an inflammatory microenvironment that promotes the development of tumours.
  • It aids in the proliferation and survival of malignant cells, promotes angiogenesis and metastasis, subverts adaptive immune responses, and alters responses to hormones and chemotherapeutic agents.
  • The molecular pathways of this cancer-related inflammation are now being unravelled, resulting in the identification of new target molecules that could lead to improved diagnosis and treatment.
  • [MeSH-minor] Gonadal Steroid Hormones / metabolism. Humans. Leukocytes / immunology. Leukocytes / metabolism. Neoplasm Invasiveness. Oncogenes / genetics. Oncogenes / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18650914.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501974; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones
  • [Number-of-references] 98
  •  go-up   go-down


44. Chitale AR: Cancer and AIDS. Indian J Pathol Microbiol; 2005 Apr;48(2):151-60
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer and AIDS.
  • The occurrence of cancer as an AIDS defined disease is a subject that has received scant attention in the Indian medical establishments and lay public.
  • It is important to know that the concept of acquired immunodeficiency syndrome was ushered in with reports of rare forms of cancers in HIV infected subjects.
  • In the developed countries 34% of AIDS patients suffer from cancer, a cancer that is very aggressive, resistant to treatment and often fatal.
  • On the other hand, incidence of cancer in patients infected with HIV virus is only 3%-4% in the Indian population.
  • Nearly all patients with AIDS in India are victims of tuberculosis and opportunistic infections.
  • Among the various cancers reported in the Indian population Kaposi's sarcoma is very rare indeed.
  • AIDS associated malignant tumours tend to be more anaplastic and disseminate fairly early.
  • The object of this review is to increase awareness of the various aspects of cancer and AIDS.
  • There is an urgent need to improve gathering of epidemiological data and to direct research effort to explain a very strikingly low incidence of cancers in Indian subjects as compared to that in the West (prevalence of 4% versus 34% among HIV infected patients).
  • [MeSH-minor] Adult. Female. Humans. Incidence. India / epidemiology. Lymphoma, AIDS-Related / epidemiology. Sarcoma, Kaposi / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16758653.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 64
  •  go-up   go-down


45. Kiertiburanakul S, Likhitpongwit S, Ratanasiri S, Sungkanuparph S: Malignancies in HIV-infected Thai patients. HIV Med; 2007 Jul;8(5):322-3
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies in HIV-infected Thai patients.
  • Of 1416 HIV-infected patients seen at Ramathibodi Hospital over a 5-year period (1999-2003), 42 were diagnosed with malignancies, giving a prevalence of 3%.
  • AIDS-related malignancies were found in 26 patients (62%).
  • The most common AIDS-related malignancies were non-Hodgkin's lymphoma (NHL) (33%), cervical cancer (21%) and Kaposi's sarcoma (KS) (5%).
  • Breast cancer was the most common non-AIDS-related malignancy (10%).
  • The 75% survival time of patients who received treatment for their malignancy was longer than that of patients who received no treatment (18.3 vs 1.2 months; P<0.01).

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561879.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  •  go-up   go-down


46. Aoki Y, Tosato G: Interactions between HIV-1 Tat and KSHV. Curr Top Microbiol Immunol; 2007;312:309-26
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the advent of the HIV-1 pandemic, a close association between HIV-1 infection and the development of selected types of cancers has been brought to light.
  • The discovery of Kaposi sarcoma-associated herpesvirus (KSHV) has led to significant advances in uncovering the virological and molecular mechanisms involved in the pathogenesis of AIDS-related malignancies.
  • Extensive evidence indicates that HIV-1 trans-activating protein Tat plays an oncogenic role in the development of KSHV-associated neoplasms.
  • Comprehensive knowledge of the functions of Tat-1 together with the KSHV genes will contribute to a better understanding of the pathogenesis of virus-associated cancers and the interaction of viruses with their hosts.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089803.001).
  • [ISSN] 0070-217X
  • [Journal-full-title] Current topics in microbiology and immunology
  • [ISO-abbreviation] Curr. Top. Microbiol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Gene Products, tat; 0 / tat Gene Products, Human Immunodeficiency Virus
  • [Number-of-references] 122
  •  go-up   go-down


47. Maggiorella L, Wen B, Frascogna V, Opolon P, Bourhis J, Deutsch E: Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model. Anticancer Res; 2005 Nov-Dec;25(6B):4357-62
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reports of dramatic improvement of AIDS-related cancers, such as primary central system lymphoma after radiation therapy as well as Kaposi's sarcoma, led to the recent discovery of the "non viral" antitumor activity of HIV protease inhibitors.
  • Thus, the antitumor effect of the latter combination is associated with the enhancement of radiation-induced apoptosis and inhibition of angiogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309240.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; O3J8G9O825 / Ritonavir
  •  go-up   go-down


48. Sloand E: Hematologic complications of HIV infection. AIDS Rev; 2005 Oct-Dec;7(4):187-96
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of HIV-infected patients with highly active antiretroviral therapy (HAART) has altered the natural history of human immunodeficiency virus (HIV) infection by decreasing the frequency of opportunistic infections and altering the expected frequency of hematologic complications and AIDS-related malignancies.
  • [MeSH-minor] Anemia / drug therapy. Anemia / etiology. Antiretroviral Therapy, Highly Active. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Neutropenia / drug therapy. Neutropenia / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425959.001).
  • [ISSN] 1139-6121
  • [Journal-full-title] AIDS reviews
  • [ISO-abbreviation] AIDS Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 105
  •  go-up   go-down


49. Bhandari M, Kempin S, Aziz MS: AIDS-related osseous Kaposi sarcoma. AIDS Read; 2007 Apr;17(4):202-3, 205
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related osseous Kaposi sarcoma.
  • We report a case of AIDS-related KS in which asymptomatic lytic bone lesions were the primary manifestations of disease.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] AIDS Read. 2007 Apr;17(4):204 [17479505.001]
  • (PMID = 17479504.001).
  • [ISSN] 1053-0894
  • [Journal-full-title] The AIDS reader
  • [ISO-abbreviation] AIDS Read
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Kaaya EE, Castaños-Velez E, Ekman M, Mwakigonja A, Carneiro P, Lema L, Kitinya J, Linde A, Biberfeld P: AIDS and non AIDS-related malignant lymphoma in Tanzania. Afr Health Sci; 2006 Jun;6(2):69-75
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS and non AIDS-related malignant lymphoma in Tanzania.
  • BACKGROUND: Malignant lymphoma (ML) in HIV patients, are second in frequency to Kaposi's sarcoma (AKS) as AIDS-defining tumors.
  • In Africa the frequency of AIDS-related lymphoma (ARL) is rare and the findings are controversial.
  • Kaposi's sarcoma (KS) lesions are now causally associated with KSHV/HHV-8 but whether African ARL shows this association is not clear.
  • METHOD: Cancer registry data was reviewed for retrospective cases.
  • OBJECTIVES: To determine the frequency and type of AIDS and non-AIDS related malignant lymphoma in Tanzania and a possible co-association with KSHV/HHV-8 and EBV.
  • These findings were not related to age, sex or type of lymphoma.
  • CONCLUSIONS: This study suggests an overall increased frequency of ML patients infected with HHV-8 in Tanzania particularly in HIV patients which may result from the well established high HHV-8 prevalence in the general population, but HHV-8 was not associated with ARL pathogenesis as reflected by lack of tumor cell infection.
  • [MeSH-major] Lymphoma / epidemiology. Lymphoma / pathology. Lymphoma, AIDS-Related / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):79-88 [9709308.001]
  • [Cites] Br J Cancer. 1997;75(11):1704-7 [9184191.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • [Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Scand J Infect Dis. 1994;26(6):749-52 [7747100.001]
  • [Cites] Int J Cancer. 1995 May 16;61(4):574-9 [7759163.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Nov 1;10(3):295-305 [7552491.001]
  • [Cites] AIDS. 2002 Mar 8;16(4):597-603 [11873003.001]
  • [Cites] J Med Virol. 2002 Oct;68(2):264-7 [12210417.001]
  • [Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):375-405 [15129649.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] N Engl J Med. 1985 Dec 19;313(25):1564-71 [2999595.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]
  • [Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):272-3 [8532016.001]
  • [Cites] Arch Intern Med. 1996 Jan 22;156(2):202-4 [8546554.001]
  • [Cites] Br J Haematol. 1995 Dec;91(4):918-20 [8547139.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):221-9 [8607449.001]
  • [Cites] Blood. 1996 May 1;87(9):3903-9 [8611719.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] J Mol Med (Berl). 1995 Dec;73(12):603-9 [8825757.001]
  • [Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]
  • [Cites] J Virol. 1997 Mar;71(3):2505-11 [9032391.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • (PMID = 16916294.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC1831982
  •  go-up   go-down


51. Akanmu AS: AIDS-associated malignancies. Afr J Med Med Sci; 2006 Dec;35 Suppl:57-70
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated malignancies.
  • A number of immunodeficiency states--both inherited (such as agammaglobulinaemia, Bloom's syndrome, hereditary telangiectasia) and acquired (e.g. immunosuppressive therapy) have been associated with varieties of cancers.
  • HIV induces more profound immunodeficiency state and it should not be difficult to imaging why cancer diagnosis is made in over 40% of HIV infected patients.
  • Impairment of normal function of natural killer cells as a result of lack of helper signals from CD4+ T-lymphocytes may be a major mechanism of increased susceptibility to cancer development in HIV infected patients.
  • Although many neoplastic diseases could occur at a frequency not higher than would be expected by chance alone, the biological behaviour of such malignancies tend to be more aggressive.
  • Three neoplastic diseases are associated so commonly with HIV infection that each of them has become recognized as an AIDS defining illness.
  • Both KS and NHL were recognized as AIDS associated cancers from the onset of the epidemic in 1981 but carcinoma of the cervix became AIDS defining in 1993.
  • [MeSH-major] HIV. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Sarcoma, Kaposi / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050776.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Nigeria
  • [Number-of-references] 114
  •  go-up   go-down


52. Cheung MC, Hicks LK, Leitch HA: Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk; 2010 Apr;10(2):E22-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma.
  • Hodgkin lymphoma (HL) is the second most common non-AIDS-defining malignancy among persons infected with HIV, and its incidence might be increasing in the current era of combination antiretroviral therapy (cART).
  • Antiretroviral therapy is commonly prescribed concomitantly with chemotherapy in the treatment of AIDS-related malignancies.
  • In particular, the potential for excessive vinca alkaloid-associated toxicity is significant, given the metabolism of drugs such as vinblastine by the 3A4 isoenzyme of the cytochrome P450 system and the inhibition of this isoenzyme by protease inhibitors.
  • We report 3 patients who experienced severe vinblastine-associated neurotoxicity during concomitant treatment with ritonavirboosted antiretrovirals.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV Infections / drug therapy. Hodgkin Disease. Lymphoma, AIDS-Related


53. Greene K, Banerjee SC: Disease-related stigma: comparing predictors of AIDS and cancer stigma. J Homosex; 2006;50(4):185-209
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease-related stigma: comparing predictors of AIDS and cancer stigma.
  • This study explores the prevalence of AIDS and cancer stigma as influenced by attitude toward homosexuality, religiosity, authoritarianism, and androgyny.
  • This study used a quasi-experimental survey design (N = 485) to examine attitude toward people with AIDS and cancer, and interaction with people with AIDS and cancer.
  • Negative attitudes toward homosexuality, high religious intensity and ideology, high authoritarianism, and low expressive emerged as factors related to more negative attitudes toward people with AIDS and unwillingness to interact with people with AIDS.
  • Attitudes toward people with cancer were generally not related to the variables.
  • Findings explore how to campaign efforts to reduce existing negative attitudes toward AIDS and homosexuality, given that gay men with AIDS are especially stigmatized.


54. Bottler T, Kuttenberger J, Hardt N, Oehen HP, Baltensperger M: Non-HIV-associated Kaposi's sarcoma of the tongue. Case report and review of the literature. Int J Oral Maxillofac Surg; 2007 Dec;36(12):1218-20
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-HIV-associated Kaposi's sarcoma of the tongue. Case report and review of the literature.
  • Kaposi's sarcoma is a frequently seen AIDS-related malignant neoplasm in the head and neck region, especially in the oral cavity, but is rarely described in the HIV-negative and non-immunosuppressed individual.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614259.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 20
  •  go-up   go-down


55. Blanes M, Belinchón I, Merino E, Portilla J, Sánchez-Payá J, Betlloch I: [Current prevalence and characteristics of dermatoses associated with human immunodeficiency virus infection]. Actas Dermosifiliogr; 2010 Oct;101(8):702-9
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current prevalence and characteristics of dermatoses associated with human immunodeficiency virus infection].
  • The frequency of opportunistic infections and AIDS-related cancers has fallen, though new health problems have developed.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20965013.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


56. Gichuhi S, Irlam JJ: Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals. Cochrane Database Syst Rev; 2007;(2):CD005643
HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This pattern is related to the co-existence of the HIV/AIDS pandemic, high HPV exposure, and solar radiation in the region.
  • SEARCH STRATEGY: Using a sensitive search strategy, we attempted to identify all relevant trials, regardless of language or publication status, from the following electronic databases; Medline/PubMed, CENTRAL, AIDSearch, EMBASE, LILACS, African Healthline, Cochrane HIV/AIDS Specialised Register, and the Cochrane Cancer Network Specialised Register.
  • We searched the clinical trial register of the US National Institutes of Health, searched the international conference proceedings of AIDS and AIDS-related cancers, and contacted individual researchers, research organisations, and pharmaceutical companies that manufacture the drugs used as interventions.
  • HIV/AIDS research has not focused on treatment of this tumour.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2013;2:CD005643 [23450564.001]
  • (PMID = 17443606.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 64
  •  go-up   go-down


57. Phatak UA: Immune reconstitution inflammatory syndrome in AIDS-related non-hodgkin's lymphoma. Indian J Med Paediatr Oncol; 2009 Oct;30(4):153-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune reconstitution inflammatory syndrome in AIDS-related non-hodgkin's lymphoma.
  • Immune Reconstitution syndrome following antiretroviral therapy is common in HIV/AIDS patients due to boosting of immunity.
  • A case is reported here wherein AIDS-related Non-Hodgkin's lymphoma patient received CHOP regimen and antiretroviral therapy.

  • HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20838562.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2930308
  • [Keywords] NOTNLM ; AIDS-related lymphoma / HIV-IRIS / IRIS
  •  go-up   go-down


58. Tulpule A: Multidrug resistance in AIDS-related lymphoma. Curr Opin Oncol; 2005 Sep;17(5):466-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance in AIDS-related lymphoma.
  • PURPOSE OF REVIEW: AIDS-related lymphoma has a decreased response rate and poorer prognosis to standard chemotherapy when compared with lymphoma in the non-HIV population.
  • In addition to the known HIV-related and lymphoma-related poor prognostic factors, this review discusses another factor, MDR-1 expression and its impact on response to therapy in patients with AIDS-related lymphoma.
  • RECENT FINDINGS: There is an increased incidence of de-novo MDR-1 expression in AIDS-related lymphoma compared with lymphoma in the non-HIV settings.
  • MDR-1 expression in AIDS-related lymphoma is associated with poor response to conventional combination chemotherapy.
  • Liposomal encapsulation of doxorubicin when substituted for doxorubicin in the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) seems to overcome P-glycoprotein-mediated drug resistance in AIDS-related lymphoma.
  • SUMMARY: The overexpression of MDR-1 gene product P-glycoprotein is an adverse prognostic factor in AIDS-related lymphoma.
  • Treatment with liposomal encapsulated doxorubicin seems to overcome the P-glycoprotein-related drug resistance.
  • This and other strategies to modulate MDR-1 should be further explored in order to improve success rates in the treatment of AIDS-related lymphoma.
  • [MeSH-major] Drug Resistance, Multiple, Viral / genetics. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / genetics

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093797.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 23
  •  go-up   go-down


59. Lavolé A, Epaud C, Rosencher L, Gounant V, Wislez M, Cadranel J: [Lung cancer in HIV-positive patients]. Rev Pneumol Clin; 2007 Jun;63(3):167-75
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung cancer in HIV-positive patients].
  • [Transliterated title] Le cancer broncho-pulmonaire chez les patients séropositifs pour le virus de l'immunodéficience humaine.
  • Since 1996, AIDS-related mortality has declined considerably with the introduction of tritherapy (HAART).
  • This decline in mortality has been associated with an increase in the proportion of deaths caused by cancers unrelated to AIDS, particularly lung cancer.
  • The risk of developing lung cancer is higher in the HIV-seropositive population than in the aged-matched general population, undoubtedly because of the high rate of smoking, particularly among drug abusers, but also because of other reasons which remain to be determined.
  • Mean age at the discovery of lung cancer in HIV+ patients is 45 years, and most are symptomatic.
  • Prospective clinical studies are needed to define a better management strategy for lung cancer in HIV-positive patients.
  • [MeSH-minor] Adenocarcinoma / complications. Age Factors. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Humans. Neoplasm Staging. Pneumonectomy. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675940.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 66
  •  go-up   go-down


60. Hoffmann C, Horst HA, Weichenthal M, Hauschild A: Malignant melanoma and HIV infection -- aggressive course despite immune reconstitution. Onkologie; 2005 Jan;28(1):35-7
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma and HIV infection -- aggressive course despite immune reconstitution.
  • BACKGROUND: Highly active antiretroviral therapy (HAART) has altered the course of most AIDS-related malignancies.


61. Stebbing J, Duru O, Bower M: Non-AIDS-defining cancers. Curr Opin Infect Dis; 2009 Feb;22(1):7-10
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-defining cancers.
  • PURPOSE OF REVIEW: Individuals with HIV infection are at higher risk for the development of a wide variety of non-AIDS-defining cancers (NADCs).
  • Although all three AIDS-defining malignancies and many NADCs are associated with viral etiopathogenesis, some, such as lung cancer, are not related to any known viral oncogenes and the reason for their increased incidence in immunosuppressed individuals remains unclear.
  • RECENT FINDINGS: The majority of the excess risk of NADC is accounted for by a limited number of specific cancers, which repeatedly occur with increased incidence in published series.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19532075.001).
  • [ISSN] 1473-6527
  • [Journal-full-title] Current opinion in infectious diseases
  • [ISO-abbreviation] Curr. Opin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


62. Silverberg MJ, Abrams DI: AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol; 2007 Sep;19(5):446-51
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era.
  • Recent literature is reviewed with respect to the incidence and risk factors for cancer in HIV patients.
  • RECENT FINDINGS: Previous studies have demonstrated substantial declines in AIDS-defining malignancies in the era of antiretroviral therapy, with clear links to better immune function.
  • Increases in non-AIDS-defining malignancies such as Hodgkin's disease, skin, lung, anal, and kidney cancers have been noted by some but not all authors.
  • Certain non-AIDS-defining malignancies may be related to immunodeficiency, although data are conflicting.
  • Recent studies have indicated that confounding by traditional risk factors, including cigarette use, may account for some of the increased risk of lung and other cancers in HIV patients.
  • SUMMARY: Non-AIDS-defining malignancies account for more morbidity and mortality than AIDS-defining malignancies in the antiretroviral therapy era.
  • Traditional risk factors play a significant role in the increased risk of non-AIDS-defining malignancies for HIV-infected individuals, but do not entirely explain the excess cancer risk.
  • Unanswered questions remain including the relationship of immunodeficiency and the risk of site-specific non-AIDS-defining malignancies, and the effect of antiretroviral therapy duration and drug class on cancer risk.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762569.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 67
  •  go-up   go-down


63. Galceran J, Marcos-Gragera R, Soler M, Romaguera A, Ameijide A, Izquierdo A, Borràs J, de Sanjosé S, Casabona J: Cancer incidence in AIDS patients in Catalonia, Spain. Eur J Cancer; 2007 Apr;43(6):1085-91
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer incidence in AIDS patients in Catalonia, Spain.
  • HIV infected people and AIDS patients develop cancer more frequently than the general population.
  • The objective of this study was to evaluate the risk of developing cancer among 15 to 69 year old AIDS patients from two geographic areas: Tarragona and Girona provinces, in north-eastern Spain.
  • We have studied invasive and in situ cancers (for all sites) among 1659 AIDS patients from +/-5 years around the date of their AIDS diagnosis by matching the population-based Cancer Registries with the AIDS Registry covering these populations.
  • Sex and age-standardised incidence ratios (SIRs) of observed-to-expected cancers were calculated by type of cancer as a measure of risk.
  • For selected types of cancers, SIRs were also calculated for HIV exposure category.
  • Compared with the general population, incidence of cancer among AIDS patients (invasive and in situ) increased 22.9 fold in men (n=142) and 21.0 fold in women (n=45).
  • High statistically significant SIRs were found for Kaposi's sarcoma (KS) (male, 486.4; female, 1030.0), non-Hodgkin's lymphoma (NHL) (male, 126.1; female, 192.8) and invasive cervical cancer (41.8).
  • High risks were also found for Hodgkin's lymphoma (31.1), liver cancer (29.4) and lung cancer (9.4) in men, and in situ cervical cancer (24.4) in women.
  • For all non-AIDS defining malignant neoplasms as a group SIRs were 3.4 in men and 2.5 in women.
  • Among men, homo/bisexuality was strongly related to risk of KS and NHL.
  • The rates of cervical cancer, Hodgkin's lymphoma, liver cancer and lung cancer were among the highest ever reported linked to HIV infection.
  • For the cervical cancer this could be attributable to the low incidence of this cancer in the general population and to the high prevalence of intravenous drug users among HIV women and probably due to poor preventive strategies in this population.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349785.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Wang X, Wang X, Liang D, Lan K, Guo W, Ren G: Classic Kaposi's sarcoma in Han Chinese and useful tools for differential diagnosis. Oral Oncol; 2010 Sep;46(9):654-6
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma (KS) is a common AIDS-related malignant neoplasm in the head and neck region, especially in the oral cavity, but is rarely described in the HIV-negative and non-immunosuppressed individual.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20656545.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


65. O'Brien MA, Whelan TJ, Villasis-Keever M, Gafni A, Charles C, Roberts R, Schiff S, Cai W: Are cancer-related decision aids effective? A systematic review and meta-analysis. J Clin Oncol; 2009 Feb 20;27(6):974-85
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are cancer-related decision aids effective? A systematic review and meta-analysis.
  • PURPOSE: Decision aids (DAs) have been developed to improve communication between health professionals and patients, and to involve patients in decisions about their health care.
  • Cancer-related decisions can be difficult due to problems in communicating complex information about prognosis and the modest benefits of available treatments.
  • We conducted a systematic review of cancer-related DAs.
  • METHODS: Randomized controlled trials (RCTs) of cancer-related DAs about screening, prevention, and treatment decision making were included.
  • CONCLUSION: Cancer-related DAs are effective in increasing patient knowledge compared with usual practice without increasing anxiety particularly in the area of cancer screening.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Choosing a Doctor or Health Care Service.
  • MedlinePlus Health Information. consumer health - Talking With Your Doctor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Evid Based Nurs. 2009 Oct;12(4):108 [19779075.001]
  • (PMID = 19124808.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


66. Bahl S, Theis B, Nishri D, Marrett LD: Changing incidence of AIDS-related Kaposi sarcoma and non-Hodgkin lymphoma in Ontario, Canada. Cancer Causes Control; 2008 Dec;19(10):1251-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing incidence of AIDS-related Kaposi sarcoma and non-Hodgkin lymphoma in Ontario, Canada.
  • OBJECTIVE: To examine the influence of the AIDS epidemic on the incidence of Kaposi sarcoma (KS) and non-Hodgkin lymphoma (NHL) in Ontario.
  • METHODS: Age-standardized incidence rates for KS and NHL from 1981 to 2000 were calculated from the population-based Ontario Cancer Registry.
  • AIDS cases were extracted from Ontario Ministry of Health and Long-Term Care reports.
  • HIV death data were obtained from the Ontario Cancer Registry.
  • RESULTS: KS was a rare cancer before the 1980s; however, incidence increased sharply between 1985 and 1995 by 13.8% per year.
  • CONCLUSIONS: The AIDS epidemic, the introduction of antiretroviral therapies, and the decrease in HIV infection rates explain the rise and decline of KS incidence in Ontario.
  • NHL incidence trends are more complex, although the AIDS epidemic explains the trends observed in younger men (in whom AIDS is more common), and for the AIDS-related subtypes.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / epidemiology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Population Surveillance. Sarcoma, Kaposi / epidemiology


67. Dhir AA, Sawant S, Dikshit RP, Parikh P, Srivastava S, Badwe R, Rajadhyaksha S, Dinshaw KA: Spectrum of HIV/AIDS related cancers in India. Cancer Causes Control; 2008 Mar;19(2):147-53
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of HIV/AIDS related cancers in India.
  • OBJECTIVE: To study the cancer pattern among HIV positive cancer cases.
  • METHOD: The study group included patients registered in the HIV Cancer clinic at the Tata Memorial Hospital (TMH), Mumbai, which is the largest tertiary referral cancer center in India.
  • We used the gender and age-specific proportions of each cancer site of the year 2002 that was recorded in the Hospital Cancer Registry to estimate an expected number of various cancer sites among HIV positive cancer patients during the period 2001-2005.
  • The observed number of site-specific cancer cases was divided by the expected number to obtain proportional incidence ratio (PIR).
  • In males, PIR was increased for anal cancer (PIR = 10.3, 95%CI 4.30-24.83), Hodgkin's disease, testicular cancer, colon cancer, and few head and neck cancer sites.
  • Among females, the PIRs for cervical cancer (PIR = 4.1, 95%CI 2.90-5.75), vaginal cancer (PIR = 7.7, 95%CI 2.48-23.85), and anal cancer (PIR = 6.5, 95%CI 0.91-45.88) were increased.
  • CONCLUSIONS: The absence of Kaposi's sarcoma and increased PIRs for certain non-AIDS defining cancers among HIV infected cancer cases indicates a different spectrum of HIV associated malignancies in this region.
  • The raised PIR for cervical cancer emphasizes the urgent need for screening programs for cervical cancer among HIV infected individuals in India.


68. Zambrowski JJ: [Cost of cancer in France: pharmaceutical expenditure as part of global patients' care]. Bull Cancer; 2008 May;95(5):535-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cost of cancer in France: pharmaceutical expenditure as part of global patients' care].
  • [Transliterated title] Le coût du cancer en France : place des dépenses pharmaceutiques dans la prise en charge des malades en oncologie.
  • The INCa, as well as the French National Health Insurance recently published, and for the first time, important reports making it possible to take stock of the cost of care for the patients treated for a cancer or a malignant hemopathy, and in particular on the pharmaceutical expenditure related to cancer.
  • The number of people with full medical coverage ("ALD") for cancer increased by 62% in 10 years, and exceeds 1.25 million people today.
  • The corresponding expenditure is close to 14 billions euros for public health insurance systems, appreciably lower than that related to the cardiovascular diseases.
  • The annual expenditure by patient treated for cancer is much lower than that related on the chronic renal failure, transplantations or the VIH-AIDS.
  • The share of the expenditure related to the medical drugs and other goods (devices) is estimated by the INCa at 13% of the total expenditure related to the care.
  • The anti-cancer drugs count for 20% of the pharmaceutical expenditure of the hospitals, of which the half related to specialities reimbursed in addition to the "T2A" fixed rates.
  • Due primarily to the new anti-cancer drugs, the expenditure for this class increased by more than 6 fold in 10 years, responsible for 37% of the total increase in hospital health care expenditure.
  • However, the share of the expenditure related to the drugs is lower for the patients treated in "ALD" for cancer than that of the whole of the ALD (19.5 vs 20%).
  • The innovating anti-cancer drugs count for less than 4% of the expenditure related to cancer, i.e. less than 0.45% of the total expenditure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541518.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


69. Wong HL, Breen EC, Pfeiffer RM, Aissani B, Martinson JJ, Margolick JB, Kaslow RA, Jacobson LP, Ambinder RF, Chanock S, Martínez-Maza O, Rabkin CS: Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study. AIDS; 2010 Apr 24;24(7):1025-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study.
  • BACKGROUND: Cytokine stimulation of B-cell proliferation may be an important causative mechanism for acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin lymphoma (NHL).
  • The Epstein-Barr virus (EBV) may be a co-factor, particularly for primary central nervous system (CNS) tumors, which are uniformly EBV-positive in the setting of AIDS.
  • Thus, we examined associations of genetic variation in IL10 and related cytokine-signaling molecules (IL10RA, CXCL12, IL13, IL4, IL4R, CCL5 and BCL6) with AIDS-related NHL risk and evaluated differences between primary CNS and systemic tumors.
  • PATIENTS AND MATERIALS: We compared 160 Multicenter AIDS Cohort Study (MACS) participants with incident lymphomas, of which 90 followed another AIDS diagnosis, to HIV-1-seropositive controls matched on duration of lymphoma-free survival post-HIV-1 infection (N = 160) or post-AIDS diagnosis (N = 90).
  • RESULTS: Carriage of at least one copy of the T allele for the IL10 rs1800871 (as compared to no copies) was associated with decreased AIDS-NHL risk specific to lymphomas arising from the CNS (CC vs. CT/TT: OR = 0.3; 95% CI 0.1, 0.7) but not systemically (CC vs. CT/TT: OR = 1.0; 95% CI 0.5, 1.9) (Pheterogeneity = 0.03).
  • Carriage of two copies of the 'low IL10' haplotype rs1800896_A/rs1800871_T/rs1800872_A was associated with decreased lymphoma risk that varied by number of copies (Ptrend = 0.02).
  • CONCLUSION: Excessive IL10 response to HIV-1 infection may be associated with increased risk of NHL, particularly in the CNS.
  • IL10 dysregulation may be an important causative pathway for EBV-related lymphomagenesis.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2000 Mar;181(3):872-80 [10720507.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3325-30 [11013271.001]
  • [Cites] EMBO J. 2000 Dec 15;19(24):6742-50 [11118209.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14467-72 [11121048.001]
  • [Cites] Arthritis Rheum. 2001 Jan;44(1):176-9 [11212157.001]
  • [Cites] J Infect Dis. 2001 Sep 15;184(6):777-80 [11517440.001]
  • [Cites] Pharmacol Ther. 2002 Sep;95(3):295-304 [12243799.001]
  • [Cites] Clin Immunol. 2003 Nov;109(2):119-29 [14597210.001]
  • [Cites] Immunogenetics. 2003 Dec;55(9):629-32 [14605776.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]
  • [Cites] Science. 1990 Jun 8;248(4960):1230-4 [2161559.001]
  • [Cites] Science. 1990 Nov 9;250(4982):830-2 [2173142.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Lancet. 1991 Oct 19;338(8773):969-73 [1681341.001]
  • [Cites] Blood. 1993 Jan 1;81(1):166-76 [8380252.001]
  • [Cites] Br J Haematol. 1995 Jun;90(2):235-43 [7794745.001]
  • [Cites] Clin Exp Allergy. 1995 Nov;25 Suppl 2:74-8; discussion 95-6 [8590350.001]
  • [Cites] J Natl Cancer Inst. 1996 May 15;88(10):675-9 [8627644.001]
  • [Cites] Acta Haematol. 1996;95(3-4):193-8 [8677742.001]
  • [Cites] Ann Intern Med. 1997 Jun 15;126(12):946-54 [9182471.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):143-9 [9792301.001]
  • [Cites] J Immunol. 1999 Feb 1;162(3):1827-35 [9973448.001]
  • [Cites] Arthritis Rheum. 1999 Jun;42(6):1101-8 [10366102.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2928-35 [16332968.001]
  • [Cites] JAMA. 2006 Sep 27;296(12):1498-506 [17003398.001]
  • [Cites] Genes Immun. 2006 Dec;7(8):615-24 [16971956.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):704-12 [17056605.001]
  • [Cites] Leuk Lymphoma. 2007 Nov;48(11):2235-8 [17990180.001]
  • [ErratumIn] AIDS. 2010 Jul 31;24(12):1973
  • (PMID = 20299965.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NCRR NIH HHS / RR / 5-M01-RR-00722; United States / NIAID NIH HHS / AI / UO1-AI-35042; United States / NCI NIH HHS / CA / R01 CA073475; United States / NIAID NIH HHS / AI / UO1-AI-37984; United States / NIAID NIH HHS / AI / UO1-AI-35040; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NIAID NIH HHS / AI / UO1-AI-35041; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NCI NIH HHS / CA / P50-CA-096888; United States / NCI NIH HHS / CA / R01-CA57152; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NCI NIH HHS / CA / R01 CA057152; United States / Intramural NIH HHS / / Z99 CA999999; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / UO1-AI-35039; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NIAID NIH HHS / AI / U01 AI035039; United States / NCI NIH HHS / CA / P50 CA096888; United States / NIAID NIH HHS / AI / UO1-AI-35043; United States / NIAID NIH HHS / AI / UO1-AI-37613; United States / NCI NIH HHS / CA / R01-CA73475
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 130068-27-8 / Interleukin-10
  • [Other-IDs] NLM/ NIHMS192123; NLM/ PMC3950937
  •  go-up   go-down


70. Kasamon YL, Ambinder RF: AIDS-related primary central nervous system lymphoma. Hematol Oncol Clin North Am; 2005 Aug;19(4):665-87, vi-vii
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related primary central nervous system lymphoma.
  • The clinical features, diagnosis, and management of AIDS-related PCNSL are reviewed.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma, AIDS-Related / pathology

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083829.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA96888; United States / NCI NIH HHS / CA / UO1 CA70062
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 100
  •  go-up   go-down


71. Chadburn A, Chiu A, Lee JY, Chen X, Hyjek E, Banham AH, Noy A, Kaplan LD, Sparano JA, Bhatia K, Cesarman E: Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol; 2009 Oct 20;27(30):5039-48
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034.
  • PATIENTS AND METHODS: We examined 81 DLBCLs from patients with AIDS in AMC010 (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] v CHOP-rituximab) and AMC034 (etoposide, doxorubicin, vincristine, prednisone, and dose-adjusted cyclophosphamide plus rituximab concurrent v sequential) clinical trials and compared the immunophenotype with survival data, Epstein-Barr virus (EBV) positivity, and CD4 counts.
  • RESULTS: The GC and non-GC subtypes of DLBCL did not differ significantly with respect to overall survival or CD4 count at cancer presentation.
  • Expression of FOXP1, Blimp-1/PRDM1, or BCL-2 was not correlated with the outcome in patients with AIDS-related DLBCL.
  • The only predictive immunohistochemical marker was found to be Ki-67, where a higher proliferation index was associated with better survival, suggesting a better response to therapy in patients whose tumors had higher proliferation rates.
  • [MeSH-major] Immunophenotyping. Ki-67 Antigen. Lymphoma, AIDS-Related / immunology. Lymphoma, Large B-Cell, Diffuse / immunology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Oncology (Williston Park). 2002 Apr;16(4):441-51, 456, 459 [12017534.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2363-7 [12424193.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):464-70 [15087665.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):414-9 [15085385.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2933-5 [15238418.001]
  • [Cites] Blood. 1988 Apr;71(4):1157-60 [3281723.001]
  • [Cites] Lancet. 1991 Feb 9;337(8737):320-2 [1671232.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1460-6 [8123837.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 1:113-6 [8172807.001]
  • [Cites] Blood. 1997 Jan 15;89(2):601-9 [9002964.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1931-9 [9586912.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):515-24 [9711914.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1065-72 [15709173.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1762-9 [15905193.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9067-72 [16172462.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):438-46 [16444194.001]
  • [Cites] Haematologica. 2006 Apr;91(4):467-74 [16585013.001]
  • [Cites] Microbes Infect. 2006 Apr;8(5):1301-7 [16697236.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 May;6(6):455-7 [16796775.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4135-42 [16943530.001]
  • [Cites] Ann Oncol. 2007 May;18(5):931-9 [17395602.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4930-5 [17299093.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Histopathology. 2007 Jul;51(1):70-9 [17593082.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):458-63 [17762571.001]
  • [Cites] Eur J Haematol. 2007 Dec;79(6):501-7 [17986209.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2816-24 [18077790.001]
  • [Cites] Annu Rev Immunol. 2008;26:133-69 [18370921.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2717-24 [18378569.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5 [18765795.001]
  • [Cites] Nat Rev Immunol. 2007 Dec;7(12):923-7 [17965637.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):920-32 [12461565.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [CommentIn] J Clin Oncol. 2010 Jun 1;28(16):e260; author reply e261-2 [20421532.001]
  • (PMID = 19752343.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / CA-121947
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  • [Other-IDs] NLM/ PMC2799056
  •  go-up   go-down


72. Martellotta F, Berretta M, Vaccher E, Schioppa O, Zanet E, Tirelli U: AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies. Curr HIV Res; 2009 Nov;7(6):634-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies.
  • In the HAART era Kaposi's sarcoma (KS) remains the second most frequent tumor in HIV-infected patients worldwide, and it has become the most common cancer in Sub-Saharan Africa.
  • KS lesions are comprised of both distinctive spindle cells of endothelial origin and a variable inflammatory infiltrate, which suggests that KS may result from reactive hyperproliferation induced by chronic inflammation, and therefore it is not a true neoplasm.
  • Treatment decisions must take into consideration the extent and the rate of tumor growth, patient's symptoms, immune system conditions and concurrent HIV-related complications.
  • The aim of this article is to provide an up-to-date review of the current status and perspectives of AIDS-related KS in the HAART era.


73. Mbulaiteye SM, Sternberg LR, Nsubuga MM, Anver MR, Mehta M, Biryahwaho B, Kambugu F, Rabkin CS, Biggar RJ: Absence of Y-chromosome sequences in tumors from African women with AIDS-related Kaposi sarcoma. Cancer Lett; 2007 Apr 18;248(2):229-33
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of Y-chromosome sequences in tumors from African women with AIDS-related Kaposi sarcoma.
  • Kaposi sarcoma (KS) occurs with relatively high frequency in immunosuppressed transplant recipients and in patients with AIDS.
  • Recently, Italian investigators reported transplant-related KS tumors bearing donor-derived antigens, suggesting possible parenteral transmission of KS as whole cells, i.e., chimeric tumors.
  • To investigate the hypothesis that KS whole cells may also be transmitted into immunocompromised persons via heterosexual acts, we tested nodular KS lesions and matched normal tissue obtained from female patients with AIDS for the presence of the Y-chromosome specific sex determining sequence (SRY).
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. DNA, Neoplasm / genetics. Disease Transmission, Infectious. Sarcoma, Kaposi / genetics. Sex-Determining Region Y Protein / analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16934394.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01 CO12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Sex-Determining Region Y Protein
  •  go-up   go-down


74. Joerger M, Huitema AD, Meenhorst PL, Schellens JH, Beijnen JH: Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Cancer Chemother Pharmacol; 2005 May;55(5):488-96
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
  • PURPOSE: Systemic chemotherapy is the treatment of choice for AIDS-related advanced Kaposi sarcoma.
  • We analysed the plasma concentrations of low-dose doxorubicin (Dx) and its metabolites doxorubicinol, 7-deoxydoxorubicinone, doxorubicinone, doxorubicinolone, and 7-deoxydoxorubicinolone in AIDS-patients to define patient-group and dose-specific pharmacokinetic parameters.
  • MATERIALS AND METHODS: A previously described high-performance liquid chromatographic (HPLC) method and a population approach with non-linear mixed effects modelling (NONMEM) were used for analysis and subsequent modelling of the time-concentration data of low-dose Dx and metabolites in seven patients with AIDS-related advanced Kaposi sarcoma.
  • [MeSH-major] AIDS-Related Opportunistic Infections / metabolism. Doxorubicin / pharmacokinetics. Sarcoma, Kaposi / metabolism

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726371.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin
  •  go-up   go-down


75. Palmateer NE, Hutchinson SJ, McLeod A, Codere G, Goldberg DJ: Comparison of deaths related to Hepatitis C and AIDS in Scotland. J Viral Hepat; 2007 Dec;14(12):870-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of deaths related to Hepatitis C and AIDS in Scotland.
  • In resource-rich countries, the incidence of and mortality from AIDS has fallen dramatically since the introduction of combination antiretroviral therapy.
  • In contrast, developed countries have observed increases in the public health burden associated with the hepatitis C virus (HCV).
  • We compared past and current trends in mortality related to HCV sequelae and HIV/AIDS in Scotland by linking death records with national databases of persons diagnosed with HCV and HIV/AIDS.
  • AIDS-related deaths increased rapidly during the late-1980s to mid-1990s and declined dramatically after 1996.
  • Deaths related to HCV (i.e., viral hepatitis, liver cancer, alcoholic liver disease, or non-alcoholic liver disease) surpassed the number of AIDS-related deaths in 1998 and increased at an average annual rate of 10.5% (95% confidence interval = 7-14%) during 1996-2005.
  • The leading underlying cause of HCV-related deaths was alcoholic liver disease (50% of deaths during 2001-2005).
  • This study highlights the increasing public health burden, vis-à-vis mortality, of HCV, when compared with HIV/AIDS in developed countries.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070290.001).
  • [ISSN] 1352-0504
  • [Journal-full-title] Journal of viral hepatitis
  • [ISO-abbreviation] J. Viral Hepat.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


76. Monforte Ad, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD, Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group: HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS; 2008 Oct 18;22(16):2143-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.
  • OBJECTIVE: To evaluate deaths from AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) in the D:A:D Study and to investigate the relationship between these deaths and immunodeficiency.
  • We used Poisson regression models to identify factors independently associated with deaths from ADM and nADM.
  • Analyses of factors associated with mortality due to nADM were repeated after excluding nADM known to be associated with a specific risk factor.
  • RESULTS: Three hundred five patients died due to a malignancy, 298 prior to the cutoff for this analysis (ADM: n = 110; nADM: n = 188).
  • In multivariable regression analyses, a two-fold higher latest CD4 cell count was associated with a halving of the risk of ADM mortality.
  • Other predictors of an increased risk of ADM mortality were homosexual risk group, older age, a previous (non-malignancy) AIDS diagnosis and earlier calendar years.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutagenesis. 2005 Mar;20(2):139-46 [15784690.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Clin Infect Dis. 2005 Sep 15;41(6):855-63 [16107986.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] AIDS. 2006 Jan 2;20(1):49-57 [16327319.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Arch Intern Med. 2006 Aug 14-28;166(15):1632-41 [16908797.001]
  • [Cites] Ann Intern Med. 2006 Sep 19;145(6):397-406 [16983127.001]
  • [Cites] Environ Mol Mutagen. 2007 Apr-May;48(3-4):239-47 [17358029.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Blood. 2000 May 1;95(9):2860-8 [10779432.001]
  • [Cites] AIDS. 2000 May 5;14(7):771-80 [10839584.001]
  • [Cites] Lancet. 2000 Oct 21;356(9239):1423-30 [11052597.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] AIDS. 2002 Aug 16;16(12):1663-71 [12172088.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2002 Jul 26;51(29):642-5 [12186222.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):505-7 [12888821.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):1993-2003 [14627784.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Int J Epidemiol. 2005 Feb;34(1):121-30 [15561752.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):407-9 [15769998.001]
  • [Cites] J Hepatol. 2005 Jun;42(6):799-805 [15973779.001]
  • (PMID = 18832878.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / 5U01AI046362-03; United States / NIAID NIH HHS / AI / U01 AI069907-02; United States / NIAID NIH HHS / AI / U01 AI046362; United States / NIAID NIH HHS / AI / 5U01AI042170-10; United States / NIAID NIH HHS / AI / U01 AI069907; United States / NIAID NIH HHS / AI / U01 AI042170
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ NIHMS113887; NLM/ PMC2715844
  • [Investigator] Collins S; Loeliger E; Tressler R; Weller I; Friis-Møller N; Worm SW; Sabin CA; Sjøl A; Lundgren JD; Sawitz A; Rickenbach M; Pezzotti P; Krum E; Gras L; Balestre E; Sundström A; Poll B; Fontas E; Torres F; Petoumenos K; Kjaer J; de Wolf F; Zaheri S; Gras L; Bronsveld W; Hillebrand-Haverkort ME; Prins JM; Bos JC; Schattenkerk JK; Geerlings SE; Godfried MH; Lange JM; van Leth FC; Lowe SH; van der Meer JT; Nellen FJ; Pogány K; van der Poll T; Reiss P; Ruys TA; Sankatsing SR; van Twillert G; van der Valk M; van Vonderen MG; Vrouenraets SM; van Vugt M; Wit FW; van Eeden A; ten Veen JH; van Dam PS; Roos JC; Brinkman K; Frissen PH; Weigel HM; Mulder JW; van Gorp EC; Meenhorst PL; Mairuhu AT; Veenstra J; Danner SA; Van Agtmael MA; Claessen FA; Perenboom RM; Rijkeboer A; van Vonderen M; Richter C; van der Berg J; van Leusen R; Vriesendorp R; Jeurissen FJ; Kauffmann RH; Koger EL; Bravenboer B; ten Napel CH; Kootstra GJ; Sprenger HG; Miesen WM; Doedens R; Scholvinck EH; ten Kate RW; van Houte DP; Polee M; Kroon FP; van den Broek; van Dissel JT; Schippers EF; Schreij G; van de Geest S; Verbon A; Koopmans PP; Keuter M; Post F; van der Ven AJ; van der Ende ME; Gyssens IC; van der Feltz M; den Hollander JG; de Marie S; Nouwen JL; Rijnders BJ; de Vries TE; Juttmann JR; van de Heul C; van Kasteren ME; St Elisabeth SM; Bonten MJ; Borleffs JC; Ellerbroek PM; Hoepelman IM; Jaspers CA; Schouten I; Schurink CA; Blok WL; Tanis AA; Groeneveld PH; Salamon R; Beylot J; Dupon M; Le Bras M; Pellegrin JL; Ragnaud JM; Dabis F; Chêne G; Jacqmin-Gadda H; Thiébaut R; Lawson-Ayayi S; Lavignolle V; Balestre E; Blaizeau MJ; Decoin M; Formaggio AM; Delveaux S; Labarerre S; Uwamaliya B; Vimard E; Merchadou L; Palmer G; Touchard D; Dutoit D; Pereira F; Boulant B; Beylot J; Morlat P; Bernard N; Bonarek M; Bonnet F; Coadou B; Gelie P; Jaubert D; Nouts C; Lacoste D; Dupon M; Dutronc H; Cipriano G; Lafarie S; Chossat I; Lacut JY; Leng B; Pellegrin JL; Mercié P; Viallard JF; Faure I; Rispal P; Cipriano C; Tchamgoué S; Le Bras M; Djossou F; Malvy D; Pivetaud JP; Ragnaud JM; Chambon D; De La Taille C; Galperine T; Lafarie S; Neau D; Ochoa A; Beylot C; Doutre MS; Bezian JH; Moreau JF; Taupin JL; Conri C; Constans J; Couzigou P; Castera L; Fleury H; Lafon ME; Masquelier B; Pellegrin I; Trimoulet P; Moreau F; Mestre C; Series C; Taytard A; Law M; Glenday K; Petoumenos K; Anderson J; Cortissos P; Mijch A; Watson K; Roth N; Nicolson J; Bloch M; Agrawal S; Franic T; Baker D; Vale R; Carr A; Cooper D; Lacey M; Hesse K; Chuah J; Lester D; Fankhauser W; Mallal S; Forsdyke C; Bulgannawar S; Calvo G; Torres F; Mateu S; Domingo P; Sambeat MA; Gatell J; Del Cacho E; Cadafalch J; Fuster M; Codina C; Sirera G; Vaqué A; Clumeck N; De Wit S; Gerard M; Kabeya K; Konopnicki D; Libois A; Payen MC; Poll B; Van Laethem Y; Neaton J; Bartsch G; El-Sadr WM; Krum E; Thompson G; Wentworth D; Luskin-Hawk R; Telzak E; El-Sadr WM; Abrams DI; Cohn D; Markowitz N; Arduino R; Mushatt D; Friedland G; Perez G; Tedaldi E; Fisher E; Gordin F; Crane RL; Sampson J; Baxter J; Kirk O; Olsen CH; Mocroft A; Phillips AN; Lundgren JD; Vetter N; Karpov I; Vassilenko A; Clumeck N; De Wit S; Poll B; Colebunders R; Machala L; Rozsypal H; Sedlacek D; Nielsen J; Benfield T; Gerstoft J; Katzenstein T; Hansen AB; Skinhøj P; Pedersen C; Zilmer K; Katlama C; Viard JP; Girard PM; Saint-Marc T; Vanhems P; Pradier C; Dabis F; Dietrich M; Manegold C; van Lunzen J; Stellbrink HJ; Staszewski S; Bieckel M; Goebel FD; Fätkenheuer C; Rockstroh J; Schmidt RE; Kosmidis J; Gargalianos P; Sambatakou H; Perdios J; Panos G; Filandras A; Banhegyi D; Mulcahy F; Yust I; Burke M; Turner D; Pollack S; Hassoun J; Sthoeger Z; Maayan S; Vella S; Chiesi A; Arici C; Pristerá R; Mazzotta F; Gabbuti A; Esposito R; Bedini A; Chirianni A; Montesarchio E; Vullo V; Santopadre P; Narciso P; Antinori A; Franci P; Zaccarelli M; Lazzarin A; Castagna A; Monforte Ad; Viksna L; Chaplinskas S; Hemmer R; Staub T; Reiss P; Bruun J; Maeland A; Ormaasen V; Knysz B; Gasiorowski J; Horban A; Prokopowicz D; Wiercinska-Drapalo A; Boron-Kaczmarska A; Pynka M; Beniowski M; Mularska E; Trocha H; Antunes F; Mansinho K; Maltez F; Duiculescu D; Babes V; Streinu-Cercel A; Vinogradova E; Rakhmanova A; Jevtovic D; Mokrás M; Staneková D; González-Lahoz J; Sanchez-Conde M; García-Benayas T; Martin-Carbonero L; Soriano V; Clotet B; Jou A; Conejero J; Ruiz L; Tural C; Gatell JM; Miró JM; Zamora L; Blaxhult A; Karlsson A; Pehrson P; Ledergerber B; Weber R; Francioli P; Telenti A; Hirschel B; Soravia-Dunand V; Furrer H; Kravchenko E; Chentsova N; Fisher M; Brettle R; Barton S; Johnson AM; Mercey D; Murphy M; Johnson MA; Weber J; Scullard G; Morfeldt L; Thulin G; Sundström A; Akerlund B; Koppel K; Karlsson A; Flamholc L; Håkangård C; Monforte Ad; Ammassari A; Antinori A; Maggiolo F; Balotta C; Bonfanti P; Capobianchi M; Castagna A; Ceccherini-Silberstein F; Cozzi-Lepri A; Monforte Ad; De Luca A; Gervasoni C; Girardi E; Lo Caputo S; Murri R; Mussini C; Puoti M; Torti C; Moroni M; Carosi G; Cauda R; Chiodo F; Monforte Ad; Di Perri G; Galli M; Iardino R; Ippolito G; Lazzarin A; Mazzotta F; Panebianco R; Pastore G; Perno CF; Montroni M; Scalise G; Costantini A; Riva A; Tirelli U; Martellotta F; Pastore G; Ladisa N; Suter F; Maggiolo F; Chiodo F; Colangeli V; Fiorini C; Carosi G; Cristini G; Torti C; Minardi C; Bertelli D; Quirino T; Manconi PE; Piano P; Pizzigallo E; D'Alessandro M; Carnevale G; Zoncada A; Ghinelli F; Sighinolfi L; Leoncini F; Mazzotta F; Pozzi M; Lo Caputo S; Grisorio B; Ferrara S; Pagano G; Cassola G; Alessandrini A; Piscopo R; Soscia F; Tacconi L; Orani A; Perini P; Tommasi D; Congedo P; Chiodera F; Castelli P; Moroni M; Lazzarin A; Rizzardini G; Caggese L; Monforte Ad; Galli A; Merli S; Pastecchia C; Moioli MC; Esposito R; Mussini C; Gori A; Cagni S; Abrescia N; Chirianni A; Izzo CM; De Marco M; Viglietti R; Manzillo E; Ferrari C; Pizzaferri P; Filice G; Bruno R; Magnani G; Ursitti MA; Arlotti M; Ortolani P; Cauda R; Andreoni M; Antinori A; Antonucci G; Narciso P; Tozzi V; Vullo V; De Luca A; Zaccarelli M; Acinapura R; De Longis P; Trotta MP; Lichtner M; Carletti F; Mura MC; Mannazzu M; Caramello P; Di Perri G; Orofino GC; Sciandra M; Raise E; Ebo F; Pellizzer G; Buonfrate D; Pradier C; Fontas E; Caissotti C; Dellamonica P; Bentz L; Bernard E; De Salvador-Guillouet F; Durant J; Mondain-Miton V; Perbost I; Prouvost-Keller B; Pugliese P; Rahelinirina V; Roger PM; Vandenbos F; Battegay M; Bernasconi E; Böni J; Bucher H; Bürgisser P; Cattacin S; Cavassini M; Dubs R; Egger M; Elzi L; Erb P; Fischer M; Flepp M; Fontana A; Francioli P; Furrer HJ; Gorgievski M; Günthard H; Hirschel B; Kaiser L; Kind C; Klimkait T; Lauper U; Ledergerber B; Opravil M; Paccaud F; Pantaleo G; Perrin L; Piffaretti JC; Rickenbach M; Schmid CR; Schüpbach J; Speck R; Telenti A; Trkola A; Vernazza P; Weber R; Yerly S
  •  go-up   go-down


77. El-Salem M, Raghunath PN, Marzec M, Liu X, Kasprzycka M, Robertson E, Wasik MA: Activation of mTORC1 signaling pathway in AIDS-related lymphomas. Am J Pathol; 2009 Aug;175(2):817-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of mTORC1 signaling pathway in AIDS-related lymphomas.
  • Using immunohistochemistry with antibodies against the phosphoserine residues in both S6rp and 4E binding protein 1, we identified the activation of the mammalian target of rapamycin (mTORC)1 pathway in 29 cases of AIDS-related lymphoma.
  • mTORC1 was also activated in the hyperplastic but not involuted follicles of HIV-associated lymphadenopathy in eight cases, supporting the notion that mTORC1 activation is a common feature of transformed lymphocytes irrespective of either their reactive or malignant phenotype.
  • These findings indicate that AIDS-related lymphoma and other histologically similar types of lymphomas that are derived from transformed B lymphocytes may display clinical responses to inhibitors that directly target mTORC1 or, possibly, upstream activators of the mTORC1 pathway.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transpl Int. 2003 Mar;16(3):202-6 [12664217.001]
  • [Cites] EMBO J. 2002 Aug 1;21(15):4070-80 [12145207.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21960-71 [12668683.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37288-96 [12867426.001]
  • [Cites] Biochimie. 2003 Aug;85(8):763-9 [14585543.001]
  • [Cites] Transplantation. 2004 Mar 15;77(5):760-2 [15021843.001]
  • [Cites] Pediatr Transplant. 2004 Jun;8(3):243-8 [15176961.001]
  • [Cites] J Biol Chem. 1991 Aug 15;266(23):14846-9 [1869521.001]
  • [Cites] J Biol Chem. 1992 Apr 25;267(12):8613-9 [1569106.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9107-11 [1409610.001]
  • [Cites] J Biol Chem. 1993 Jul 25;268(21):15900-5 [8340414.001]
  • [Cites] J Biol Chem. 1993 Nov 15;268(32):24442-8 [8226994.001]
  • [Cites] J Biol Chem. 1994 Feb 25;269(8):5918-25 [8119935.001]
  • [Cites] J Immunol. 1994 Jun 1;152(11):5429-37 [8189062.001]
  • [Cites] EMBO J. 1996 Oct 1;15(19):5256-67 [8895571.001]
  • [Cites] Immunol Lett. 1999 Jun 1;68(2-3):301-9 [10424436.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] J Virol. 2005 May;79(9):5499-506 [15827164.001]
  • [Cites] Cell. 2005 Apr 22;121(2):179-93 [15851026.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):19937-47 [15760907.001]
  • [Cites] Nephrol Dial Transplant. 2005 Aug;20(8):1748-51 [15919698.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7800-8 [16140948.001]
  • [Cites] Microsc Res Tech. 2005 Nov;68(3-4):168-75 [16276515.001]
  • [Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):195-9 [16404421.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5466-71 [16567633.001]
  • [Cites] Am J Kidney Dis. 2006 May;47(5):e67-72 [16632009.001]
  • [Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • [Cites] Cancer Cell. 2006 Aug;10(2):133-43 [16904612.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):729-34 [16915295.001]
  • [Cites] J Biol Chem. 2006 Sep 15;281(37):26904-13 [16816403.001]
  • [Cites] Oncogene. 2006 Oct 16;25(48):6347-60 [17041621.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4156-62 [16912221.001]
  • [Cites] Lab Invest. 2007 Jan;87(1):29-39 [17075574.001]
  • [Cites] Transplant Proc. 2007 May;39(4):1267-71 [17524950.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Blood. 2007 Jul 1;110(1):278-86 [17363738.001]
  • [Cites] Transplant Proc. 2007 Jul-Aug;39(6):2036-7 [17692685.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5606-14 [17353907.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2181-9 [18025151.001]
  • [Cites] Transpl Int. 2008 Jun;21(6):605-8 [18282244.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]
  • [Cites] Biochem J. 1999 Dec 1;344 Pt 2:427-31 [10567225.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4285-90 [10759564.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3504-13 [10910062.001]
  • [Cites] Transplantation. 2003 May 27;75(10):1710-7 [12777861.001]
  • (PMID = 19608873.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA089194; United States / NIDCR NIH HHS / DE / R01 DE017337; United States / NCI NIH HHS / CA / R01-CA89194; United States / NIDCR NIH HHS / DE / R01-DE-017337
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Phospho-Specific; 0 / Multiprotein Complexes; 0 / Proteins; 0 / Transcription Factors; 0 / mechanistic target of rapamycin complex 1; 17885-08-4 / Phosphoserine; EC 2.7.1.1 / TOR Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2716976
  •  go-up   go-down


78. Kanmogne GD: Noninfectious pulmonary complications of HIV/AIDS. Curr Opin Pulm Med; 2005 May;11(3):208-12
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninfectious pulmonary complications of HIV/AIDS.
  • PURPOSE OF REVIEW: This article reviews recent findings on noninfectious pulmonary complications of HIV/AIDS, with a focus on HIV/AIDS-related lung malignancies and pulmonary hypertension, and discusses their incidence in the highly active antiretroviral therapy (HAART) era.
  • RECENT FINDINGS: Noninfectious pulmonary complications of HIV/AIDS are now recognized as important contributors to morbidity and mortality in HIV-infected patients.
  • This is especially the case for HIV-related lung cancer and other non-AIDS-defining malignancies, which are now being diagnosed with increased frequency in HIV-infected patients.
  • The incidence of Kaposi sarcoma and AIDS-related lymphoma has decreased in the HAART era, but compared with the general population, the risk of these malignancies and pulmonary hypertension is still very high in HIV-infected patients.
  • Concurrent use of HAART and chemotherapy improves prognosis and survival of patients with AIDS-related lymphoma.
  • For patients with HIV-related pulmonary hypertension, some studies show no beneficial effect of HAART whereas other reports show that HAART improves patient survival and response to antihypertensive treatment.
  • SUMMARY: The beneficial effect of HAART and improved immune response on the treatment of Kaposi sarcoma and AIDS-related lymphoma suggests that HIV or viral-induced immunosuppression plays an important role in the development of these malignancies.
  • Evidence from current studies suggests that HAART does not protect against HIV-related lung cancer.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / epidemiology. Hypertension, Pulmonary / epidemiology. Lung Neoplasms / epidemiology. Lymphoma, AIDS-Related / epidemiology. Sarcoma, Kaposi / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15818181.001).
  • [ISSN] 1070-5287
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / 1KO1MH068214-1
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


79. Little RF, Pluda JM, Wyvill KM, Rodriguez-Chavez IR, Tosato G, Catanzaro AT, Steinberg SM, Yarchoan R: Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood; 2006 Jun 15;107(12):4650-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma.
  • We initiated a phase 1 pilot study of IL-12 in 32 patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS) whose KS was progressing while on antiretroviral therapy.
  • These results provide preliminary evidence that IL-12 has substantial activity against AIDS-related KS with acceptable toxicity and warrants further investigation for this indication.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1876-83 [10561228.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):405-8 [9670053.001]
  • [Cites] Virology. 2000 Jan 5;266(1):17-25 [10612656.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):180-5 [10697276.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1678-92 [10815886.001]
  • [Cites] AIDS. 2000 May 26;14(8):987-93 [10853980.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2593-602 [10893291.001]
  • [Cites] J Infect Dis. 2000 Oct;182(4):1070-6 [10979901.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4873-80 [10987301.001]
  • [Cites] J Infect Dis. 2001 Apr 1;183(7):1116-20 [11237839.001]
  • [Cites] Gynecol Oncol. 2001 Jul;82(1):7-10 [11426954.001]
  • [Cites] Blood. 2002 Jan 1;99(1):67-74 [11756154.001]
  • [Cites] AIDS. 2002 May 24;16(8):1147-54 [12004273.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):373-82 [12044013.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3686-95 [12473577.001]
  • [Cites] Mol Psychiatry. 2002;7(10):1107-14 [12476326.001]
  • [Cites] J Infect Dis. 2003 Jan 1;187(1):149-53 [12508160.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):76-83 [12538454.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):23-36 [12559173.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2876-82 [12885804.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):399-402 [14752065.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):957-64 [14984966.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5432-8 [15328181.001]
  • [Cites] N Engl J Med. 1983 May 5;308(18):1071-6 [6835320.001]
  • [Cites] Ann Intern Med. 1984 May;100(5):671-6 [6712031.001]
  • [Cites] J Biol Response Mod. 1985 Aug;4(4):358-64 [3928825.001]
  • [Cites] Science. 1989 Jan 13;243(4888):223-6 [2643161.001]
  • [Cites] J Exp Med. 1989 Sep 1;170(3):827-45 [2504877.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1201-7 [2671281.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(17):6808-12 [2204066.001]
  • [Cites] Int J Cancer. 1991 Mar 12;47(5):692-6 [2004849.001]
  • [Cites] J Exp Med. 1991 Apr 1;173(4):869-79 [1672545.001]
  • [Cites] Immunol Today. 1991 Oct;12(10):346-8 [1683536.001]
  • [Cites] J Exp Med. 1992 Mar 1;175(3):779-88 [1346796.001]
  • [Cites] J Immunol. 1993 Sep 1;151(5):2444-52 [8103066.001]
  • [Cites] J Exp Med. 1993 Oct 1;178(4):1223-30 [8104230.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Aug;2(8):406-15; quiz 423 [16130937.001]
  • [Cites] Science. 1993 Dec 10;262(5140):1721-4 [7903123.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):409-17 [9815699.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4044-58 [10361101.001]
  • [Cites] Blood. 1999 Aug 1;94(3):902-8 [10419880.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):990-8 [15598977.001]
  • [Cites] J Leukoc Biol. 1994 Feb;55(2):280-8 [7905508.001]
  • [Cites] J Immunol. 1994 Aug 15;153(4):1697-706 [7913943.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] AIDS. 1994 Dec;8(12):1695-9 [7534090.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1181-5 [7700310.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2114-23 [7718882.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 19;87(8):581-6 [7538593.001]
  • [Cites] J Exp Med. 1995 Jul 1;182(1):155-62 [7540647.001]
  • [Cites] Blood. 1996 May 1;87(9):3877-82 [8611715.001]
  • [Cites] J Leukoc Biol. 1996 May;59(5):623-30 [8656046.001]
  • [Cites] J Infect Dis. 1996 Jul;174(1):46-53 [8656012.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3085-92 [9294471.001]
  • [Cites] Science. 1997 Oct 10;278(5336):290-4 [9323208.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):86-9 [9422510.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1183-91 [9607576.001]
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1047-53 [10594750.001]
  • (PMID = 16507779.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / SC / Z01 SC006737-14; United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / CXCL10 protein, human; 0 / Chemokine CXCL10; 0 / Chemokines, CXC; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma; EC 2.6.1.- / Transaminases
  • [Other-IDs] NLM/ PMC1475826
  •  go-up   go-down


80. Zucchetto A, Suligoi B, De Paoli A, Pennazza S, Polesel J, Bruzzone S, Rezza G, De Paoli P, Dal Maso L, Serraino D: Excess mortality for non–AIDS-defining cancers among people with AIDS. Clin Infect Dis; 2010 Nov 1;51(9):1099-101
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excess mortality for non–AIDS-defining cancers among people with AIDS.
  • During the period 1999–2006, non–AIDS-defining cancers accounted for 7.4% of deaths among Italian people with AIDS.
  • The risk of death was 6.6-fold higher than in the general population, being particularly elevated for virus-related cancers.
  • The study findings highlighted the importance of monitoring the cancer burden on mortality for people with AIDS.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20879866.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


81. Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, Prins M, CASCADE Collaboration: Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS; 2006 Mar 21;20(5):741-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Causes of death (COD) were categorized into three AIDS-related and seven non-AIDS-related causes.
  • Pre-HAART, AIDS opportunistic infections (OI) was the most common COD, followed by unknown and HIV/AIDS-unspecified.
  • In the HAART era, the cumulative incidence for all AIDS-related COD decreased, OI remaining the most important.
  • The cumulative risk of death from AIDS-related malignancies, OI and non-AIDS-related malignancies decreased significantly among homosexual men (MSM), whereas the risk of dying from (un)-intentional death increased significantly among injecting drug users (IDU).
  • A non-significant increase in hepatitis/liver-related death was seen in MSM, IDU and haemophiliacs.
  • OI remain the most common COD in the HAART era, suggesting that AIDS-related events will continue to be important in the future.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / mortality. Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Cohort Studies. Disease Progression. Female. Follow-Up Studies. HIV Seropositivity. Hepatitis / mortality. Hepatitis / virology. Humans. Incidence. Lymphoma, AIDS-Related / mortality. Lymphoma, AIDS-Related / virology. Male. Multivariate Analysis. RNA, Viral / blood. Risk. Substance Abuse, Intravenous


82. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ, HIV/AIDS Cancer Match Study: Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS; 2006 Aug 1;20(12):1645-54
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in cancer risk among people with AIDS in the United States 1980-2002.
  • BACKGROUND: People with AIDS have heightened cancer risk from immunosuppression.
  • HAART has been available since 1996 and has reduced AIDS-related mortality, but there are few large-scale studies on cancer trends.
  • METHODS: AIDS and cancer registries in 11 US regions (1980-2002) were used to identify cancers in 375 933 people with AIDS.
  • Cancer risk relative to the general population was measured using the standardized incidence ratio (SIR), focusing on the 2 years after AIDS onset for those with AIDS in 1990-1995 and 1996-2002 (HAART era).
  • RESULTS: Between 1990-1995 and 1996-2002, risk declined for the two major AIDS-defining cancers: Kaposi sarcoma [(KS) n = 5131; SIR, 22 100 and 3640, respectively; P < 0.0001] and non-Hodgkin lymphoma [(NHL) n = 3412; SIR, 53.2 and 22.6, respectively; P < 0.0001].
  • Risk of cervical cancer did not change (n = 64; SIR, 4.2 and 5.3, respectively; P = 0.33).
  • Among non-AIDS malignancies, lung cancer was most common, but risk declined between 1990-1995 and 1996-2002 (n = 344; SIR, 3.3 and 2.6, respectively; P = 0.02).
  • CONCLUSIONS: Dramatic declines in KS and NHL were temporally related to improving therapies, especially introduction of HAART, but those with AIDS remain at marked risk.
  • Among non-AIDS-related cancers, a recent increase in Hodgkin lymphoma was observed.


83. Stalmeier PF, Roosmalen MS: Concise evaluation of decision aids. Patient Educ Couns; 2009 Jan;74(1):104-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concise evaluation of decision aids.
  • OBJECTIVE: Decision aids purport to help patients make treatment related choices.
  • Several instruments exist to evaluate decision aids.
  • METHODS: Two different decision aids were randomized in patients at high risk for breast and ovarian cancer.
  • Three factors were identified related to Information, Well-being and Decision Making.
  • CONCLUSION: Four single items, 'the amount of information received for decision making,' 'strength of preference,' 'I weighed the pros and cons,' and 'General Health,' were adequately responsive to the decision aids.
  • PRACTICE IMPLICATIONS: These items might be considered for inclusion in questionnaires to evaluate decision aids.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18775622.001).
  • [ISSN] 0738-3991
  • [Journal-full-title] Patient education and counseling
  • [ISO-abbreviation] Patient Educ Couns
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


84. Simard EP, Pfeiffer RM, Engels EA: Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med; 2010 Aug 9;170(15):1337-45
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of cancer risk late after AIDS onset in the United States.
  • BACKGROUND: Persons living with AIDS today remain at elevated cancer risk.
  • We conducted this study to assess long-term cancer risk among persons with AIDS relative to the general population and the impact of HAART on cancer incidence.
  • METHODS: Records of 263 254 adults and adolescents with AIDS (1980-2004) from 15 US regions were matched to cancer registries to capture incident cancers during years 3 through 5 and 6 through 10 after AIDS onset.
  • Rate ratios (RRs) were used to compare cancer incidence before and after 1996 to assess the impact of availability of HAART.
  • RESULTS: Risk was elevated for the 2 major AIDS-defining cancers: Kaposi sarcoma (SIRs, 5321 and 1347 in years 3-5 and 6-10, respectively) and non-Hodgkin lymphoma (SIRs, 32 and 15).
  • Incidence of both malignancies declined in the HAART era (1996-2006).
  • Risk was elevated for all non-AIDS-defining cancers combined (SIRs, 1.7 and 1.6 in years 3-5 and 6-10, respectively) and for the following specific non-AIDS-defining cancers: Hodgkin lymphoma and cancers of the oral cavity and/or pharynx, tongue, anus, liver, larynx, lung and/or bronchus, and penis.
  • Anal cancer incidence increased between 1990-1995 and 1996-2006 (RR, 2.9; 95% confidence interval [CI], 2.1-4.0), as did that of Hodgkin lymphoma (RR, 2.0; 95% CI, 1.3-2.9).
  • CONCLUSION: Among people who survived for several years or more after an AIDS diagnosis, we observed high risks of AIDS-defining cancers and increasing incidence of anal cancer and Hodgkin lymphoma.
  • [MeSH-minor] Adolescent. Adult. Anus Neoplasms / epidemiology. Anus Neoplasms / virology. Bronchial Neoplasms / epidemiology. Bronchial Neoplasms / virology. Female. Humans. Incidence. Laryngeal Neoplasms / epidemiology. Laryngeal Neoplasms / virology. Liver Neoplasms / epidemiology. Liver Neoplasms / virology. Lung Neoplasms / epidemiology. Lung Neoplasms / virology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / virology. Male. Middle Aged. Mouth Neoplasms / epidemiology. Mouth Neoplasms / virology. Penile Neoplasms / epidemiology. Penile Neoplasms / virology. Risk Assessment. Risk Factors. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / virology. Time Factors. United States / epidemiology. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1227-35 [11423255.001]
  • [Cites] Ann Intern Med. 2009 Feb 17;150(4):283-4; author reply 284-5 [19221387.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4 [19357635.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5737-42 [19336755.001]
  • [Cites] Stat Med. 2000 Feb 15;19(3):335-51 [10649300.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Oct 1;25(2):115-23 [11103041.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] AIDS. 2004 Jul 2;18(10):1393-401 [15199315.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Am J Public Health. 1995 Nov;85(11):1552-5 [7485671.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] Lancet. 1998 Jun 6;351(9117):1682-6 [9734884.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] JAMA. 1999 Jun 23-30;281(24):2305-15 [10386555.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41 [10430217.001]
  • [Cites] Clin Infect Dis. 2005 Feb 1;40(3):490-1 [15668878.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] AIDS Educ Prev. 2005 Dec;17(6 Suppl B):39-48 [16401181.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34 [16878047.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):642-8 [16868538.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Ann Epidemiol. 2008 Mar;18(3):230-4 [18083545.001]
  • [Cites] HIV Med. 2008 Apr;9(4):196-202 [18366443.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [CommentIn] Arch Intern Med. 2010 Aug 9;170(15):1345-6 [20696959.001]
  • (PMID = 20696958.001).
  • [ISSN] 1538-3679
  • [Journal-full-title] Archives of internal medicine
  • [ISO-abbreviation] Arch. Intern. Med.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010150-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS212628; NLM/ PMC2921231
  •  go-up   go-down


85. Ramírez-Marrero FA, Smit E, De La Torre-Feliciano T, Pérez-Irizarry J, Miranda S, Cruz M, Figueroa-Vallés NR, Crespo CJ, Nazario CM: Risk of cancer among Hispanics with AIDS compared with the general population in Puerto Rico: 1987-2003. P R Health Sci J; 2010 Sep;29(3):256-64
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of cancer among Hispanics with AIDS compared with the general population in Puerto Rico: 1987-2003.
  • BACKGROUND: The risk of cancer among Hispanics with Acquired Immune Deficiency Syndrome (AIDS) in the United States and Puerto Rico (PR) has not been well described.
  • The purpose of this study was to determine the risk of AIDS related and non-AIDS related cancers among Hispanics with AIDS in PR.
  • METHODS: A probabilistic record linkage of the PR AIDS Surveillance Program and PR Central Cancer Registry databases was conducted.
  • AIDS cases were grouped according to year of AIDS onset and antiretroviral therapy availability: 1987-1989 (limited availability), 1990-1995 (mono and dual therapy), and 1996-2003 (highly active antiretroviral therapy: HAART).
  • Cancer risk was described using the standardized incidence ratios (SIR).
  • RESULTS: A total of 612 cancers were identified after 3 months of AIDS diagnosis: 409 (66.7%) AIDS related and 203 (33.1%) non-AIDS related.
  • Although a decreasing trend in the risk of AIDS and non-AIDS related cancers was observed, the risk for both remained higher in the AIDS group compared to the general population in PR.
  • Non-AIDS related cancers with higher risk during the HAART availability were: oropharyngeal, anal, liver, larynx, eye and orbit, Hodgkin lymphoma, and vaginal.
  • CONCLUSION: Hispanics with AIDS in PR consistently showed a greater risk of AIDS and non-AIDS related cancers compared to the general population in PR and that has not changed over time.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20799513.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA096257; United States / NCI NIH HHS / CA / P20 CA096256
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Puerto Rico
  •  go-up   go-down


86. Kimel M, Leidy NK, Mannix S, Dixon J: Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease. Value Health; 2008 Jan-Feb;11(1):57-75
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease.
  • OBJECTIVES: Anemia, defined as having low levels of hemoglobin (HGB), is caused by disease-related (e.g., bone marrow suppression, nutritional deficiency) or treatment-related (e.g., chemotherapy, antiretroviral therapy) factors.
  • Although epoetin alfa has been shown to improve HGB outcomes in cancer, HIV/AIDS, and chronic kidney disease (CKD), these results have been viewed in isolation, rather than across populations.
  • The purpose of this article is to review findings from trials that evaluated the impact of epoetin alfa on HGB and health-related quality of life (HRQL) across various populations with different underlying causes of anemia.
  • Statistically significant improvements in HGB were generally seen (1) between groups for cancer patients receiving epoetin alfa compared with those receiving placebo or standard of care (SOC) (between-group differences in changes from baseline to end point ranging from 1.2 to 1.9 g/dl); and (2) within groups for HIV/AIDS and CKD patients receiving epoetin alfa (changes from baseline to end point of 2.5 and 2.9 g/dl and 2.7 g/dl, respectively).
  • Statistically and clinically significant improvements in HRQL, particularly with regard to fatigue, were seen across chronic conditions based on the Linear Analog Scale Assessment energy scale; where improvements of at least 8 mm-considered clinically relevant-were generally seen (1) between groups for cancer patients receiving epoetin alfa compared with those receiving placebo or SOC (differences in changes from baseline to end point from 0.8 to 19.8 mm); and (2) within groups for HIV/AIDS and CKD patients receiving epoetin alfa (changes from baseline to end point of 23 and 25 mm and 28 mm, respectively).
  • CONCLUSIONS: Results of published clinical trials suggest that treatment of anemia associated with cancer, HIV/AIDS and CKD can have a significant impact on HRQL, particularly fatigue, and that this impact is both statistically and clinically significant.


87. Shebl FM, Engels EA, Goedert JJ, Chaturvedi AK: Pulmonary infections and risk of lung cancer among persons with AIDS. J Acquir Immune Defic Syndr; 2010 Nov;55(3):375-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary infections and risk of lung cancer among persons with AIDS.
  • Lung cancer risk is significantly increased among persons with AIDS (PWA), and increased smoking may not explain all of the elevated risk, suggesting a role for additional cofactors.
  • We investigated whether AIDS-defining pulmonary infections (recurrent pneumonia, Pneumocystis jirovecii pneumonia, and pulmonary tuberculosis) affected the risk of subsequent lung cancer over 10 years after AIDS onset among 322,675 PWA, whose records were linked with cancer registries in 11 US regions.
  • We assessed lung cancer hazard ratios (HRs) using Cox regression and indirectly adjusted HRs for confounding by smoking.
  • Individuals with recurrent pneumonia (n = 5317) were at significantly higher lung cancer risk than those without [HR = 1.63, 95% confidence interval (CI) = 1.08 to 2.46, adjusted for age, race, sex, HIV acquisition mode, CD4 count, and AIDS diagnosis year].
  • Lung cancer risk was unrelated to tuberculosis [(n = 13,878) HR = 1.12, 95% CI = 0.82 to 1.53] or Pneumocystis jirovecii pneumonia [(n = 69,771) HR = 0.97, 95% CI = 0.80 to 1.18].
  • The increased lung cancer risk associated with recurrent pneumonia supports the hypothesis that chronic pulmonary inflammation arising from infections contributes to lung carcinogenesis.


88. Udhrain A, Skubitz KM, Northfelt DW: Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma. Int J Nanomedicine; 2007;2(3):345-52
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma.
  • Since the onset of the HIV pandemic in the 1980s, the incidence of Kaposi's sarcoma has increased markedly in Africa and continues to be a significant problem in association with AIDS in Western countries.
  • Many therapies have been demonstrated to be effective in the treatment of HIV-related Kaposi's sarcoma, including alitretinoin gel, interferon alpha, and various forms of cytotoxic chemotherapy.
  • However, as reviewed in this report, pegylated liposomal doxorubicin has been established as the treatment of choice for patients with AIDS-associated Kaposi's sarcoma in Western countries.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Feb;16(2):683-91 [9469358.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):653-9 [9053490.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2445-51 [9667262.001]
  • [Cites] Aust N Z J Med. 1998 Dec;28(6):777-83 [9972406.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6 Suppl 13):5-15 [15717735.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6 Suppl 13):16-35 [15717736.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3432-7 [10589755.001]
  • [Cites] Oncology (Williston Park). 2000 Jun;14(6):867-78; discussion 878, 881-3, 887- [10887636.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):878-83 [11313176.001]
  • [Cites] Cancer Invest. 2001;19(6):573-80 [11486699.001]
  • [Cites] HIV Clin Trials. 2001 Sep-Oct;2(5):429-37 [11673818.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):399-402 [14752065.001]
  • [Cites] Nature. 1988 Oct 13;335(6191):606-11 [2845275.001]
  • [Cites] BMJ. 1991 Jan 26;302(6770):203-7 [1998759.001]
  • [Cites] Am J Pathol. 1993 Jul;143(1):10-4 [8317543.001]
  • [Cites] Lancet. 1993 Aug 21;342(8869):497 [8102452.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1993;5(6):372-4 [8305358.001]
  • [Cites] J Acquir Immune Defic Syndr. 1994 May;7(5):463-8 [8158540.001]
  • [Cites] Clin Investig. 1994 Jun;72(6):417-23 [7950152.001]
  • [Cites] Res Virol. 1994 May-Aug;145(3-4):261-9 [7800953.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1994;6(5):294-6 [7530036.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):914-20 [7707119.001]
  • [Cites] Mayo Clin Proc. 1995 Sep;70(9):869-79 [7643641.001]
  • [Cites] Am J Health Syst Pharm. 1995 Sep 15;52(18):2001-4 [8528867.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):989-94 [8611437.001]
  • [Cites] J Clin Pharmacol. 1996 Jan;36(1):55-63 [8932544.001]
  • [Cites] Eur J Med Res. 1998 Feb 21;3(1-2):13-9 [9512962.001]
  • (PMID = 18019833.001).
  • [ISSN] 1176-9114
  • [Journal-full-title] International journal of nanomedicine
  • [ISO-abbreviation] Int J Nanomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Liposomes; 30IQX730WE / Polyethylene Glycols
  • [Number-of-references] 35
  • [Other-IDs] NLM/ PMC2676669
  •  go-up   go-down


89. Nsubuga MM, Biggar RJ, Combs S, Marshall V, Mbisa G, Kambugu F, Mehta M, Biryahwaho B, Rabkin CS, Whitby D, Mbulaiteye SM: Human herpesvirus 8 load and progression of AIDS-related Kaposi sarcoma lesions. Cancer Lett; 2008 May 18;263(2):182-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human herpesvirus 8 load and progression of AIDS-related Kaposi sarcoma lesions.
  • We investigated these relationships in persons with AIDS.
  • METHODS: Newly diagnosed patients with AIDS-related KS attending Mulago Hospital, in Kampala, Uganda, were assessed for KS burden and progression by questionnaire and medical examination.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2000 May;181(5):1562-8 [10823754.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Blood. 2001 May 15;97(10):3244-50 [11342455.001]
  • [Cites] J Invest Dermatol. 2001 Oct;117(4):858-63 [11676823.001]
  • [Cites] J Clin Microbiol. 2001 Dec;39(12):4269-73 [11724831.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):155-8 [11857400.001]
  • [Cites] J Infect Dis. 2002 Jul 1;186(1):110-3 [12089670.001]
  • [Cites] AIDS. 2003 Jan 24;17(2):215-22 [12545082.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] J Clin Microbiol. 2005 Sep;43(9):4840-3 [16145154.001]
  • [Cites] Int J Epidemiol. 2005 Oct;34(5):1110-7 [16043440.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):621-7 [16410791.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1504-9 [16705315.001]
  • [Cites] J Virol. 2006 Jul;80(14):7037-51 [16809309.001]
  • [Cites] Cancer Lett. 2007 Apr 18;248(2):229-33 [16934394.001]
  • [Cites] AIDS. 2007 Jul 31;21(12):1541-5 [17630548.001]
  • [Cites] Clin Infect Dis. 2003 May 1;36(9):1144-51 [12715309.001]
  • [Cites] J Virol. 2003 Jun;77(12):6761-8 [12767996.001]
  • [Cites] AIDS. 2003 Aug 15;17(12):1847-51 [12891072.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1330-5 [12953087.001]
  • [Cites] AIDS Res Hum Retroviruses. 2004 Jul;20(7):704-8 [15307914.001]
  • [Cites] J Med Virol. 2004 Nov;74(3):390-6 [15368522.001]
  • [Cites] J Virol. 2004 Nov;78(21):11707-14 [15479812.001]
  • [Cites] J Virol Methods. 2001 Feb;91(2):109-17 [11164492.001]
  • (PMID = 18234418.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / Intramural NIH HHS / / Z01 CP010150-08; United States / Intramural NIH HHS / / Z01 CP010176-07; United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Other-IDs] NLM/ NIHMS49037; NLM/ PMC2440724
  •  go-up   go-down


90. Haldorsen IS, Kråkenes J, Goplen AK, Dunlop O, Mella O, Espeland A: AIDS-related primary central nervous system lymphoma: a Norwegian national survey 1989-2003. BMC Cancer; 2008;8:225
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related primary central nervous system lymphoma: a Norwegian national survey 1989-2003.
  • BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a frequent complication in acquired immunodeficiency syndrome (AIDS).
  • The objective of this survey was to investigate incidence, clinical features, radiological findings, histologic diagnosis, treatment and outcome for all patients with histologically verified AIDS-related PCNSL diagnosed in Norway in 1989-2003.
  • METHODS: We identified the patients by chart review of all cases recorded as PCNSL in The Norwegian Cancer Registry (by law recording all cases of cancer in Norway) and all cases recorded as AIDS-related PCNSL in the autopsy registry at a hospital having 67% autopsy rate and treating 59% of AIDS patients in Norway, from 1989 to 2003.
  • We used person-time techniques to calculate incidence rates of PCNSL among AIDS patients based on recordings on AIDS at the Norwegian Surveillance System for Communicable Diseases (by law recording all cases of AIDS in Norway).
  • RESULTS: Twenty-nine patients had histologically confirmed, newly diagnosed AIDS-related PCNSL in Norway from 1989-2003.
  • AIDS patients had 5.5% lifetime risk of PCNSL.
  • CONCLUSION: This is the first national survey to confirm decreasing incidence of AIDS-related PCNSL.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / epidemiology. Central Nervous System Neoplasms / complications. Central Nervous System Neoplasms / epidemiology. Lymphoma, AIDS-Related / epidemiology

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2003 Aug 15;17(12):1787-93 [12891064.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2627-36 [15197806.001]
  • [Cites] HIV Med. 2004 Sep;5(5):377-84 [15369514.001]
  • [Cites] AIDS. 1995 Nov;9(11):1243-50 [8561977.001]
  • [Cites] J Natl Cancer Inst. 1996 May 15;88(10):675-9 [8627644.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 1;14(4):351-4 [9111477.001]
  • [Cites] Neuroimaging Clin N Am. 1997 May;7(2):281-96 [9113691.001]
  • [Cites] AIDS. 1998 May 28;12(8):952-4 [9631151.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 1;18(4):365-71 [9704942.001]
  • [Cites] Crit Rev Oncog. 1998;9(3-4):199-208 [10201628.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):207-15 [15621803.001]
  • [Cites] HIV Med. 2005 Mar;6(2):66-78 [15807712.001]
  • [Cites] MMWR Recomm Rep. 2004 Dec 17;53(RR-15):1-112 [15841069.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):665-87, vi-vii [16083829.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] J Neurovirol. 2005;11 Suppl 3:38-44 [16540454.001]
  • [Cites] Cancer. 2007 Oct 15;110(8):1803-14 [17721992.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):269-76 [10563433.001]
  • [Cites] AIDS. 2000 Jan 7;14(1):69-74 [10714569.001]
  • [Cites] Neurology. 2000 Oct 24;55(8):1194-200 [11071499.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Dec 15;25(5):451-8 [11141245.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Eur J Epidemiol. 2001;17(5):479-89 [11855582.001]
  • [Cites] Front Biosci. 2004 Jan 1;9:632-46 [14766397.001]
  • (PMID = 18684320.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2525658
  •  go-up   go-down


91. Qi Y, Martin MP, Gao X, Jacobson L, Goedert JJ, Buchbinder S, Kirk GD, O'Brien SJ, Trowsdale J, Carrington M: KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog; 2006 Aug;2(8):e79
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show that this genotype confers dual protection over the course of HIV disease; early direct containment of HIV viral load, and late specific defense against opportunistic infections, but not AIDS-related malignancies.
  • The double protection of KIR3DS1/Bw4-80I in an etiologically complex disease such as AIDS, along with the disease specificity of its effects is conceptually novel and underscores the intricacy of host immunogenetics against HIV/AIDS.
  • [MeSH-major] AIDS-Related Opportunistic Infections / genetics. Acquired Immunodeficiency Syndrome / genetics. HLA-B Antigens / genetics. Killer Cells, Natural / immunology. Receptors, Immunologic / genetics
  • [MeSH-minor] Disease Progression. HIV Seropositivity. HIV-1. Humans. Immunocompromised Host. Immunosuppression. Lymphoma, AIDS-Related / genetics. Lymphoma, AIDS-Related / immunology. Receptors, KIR. Receptors, KIR3DS1. Sarcoma, Kaposi / genetics. Sarcoma, Kaposi / immunology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2004 Dec 9;432(7018):769-75 [15592417.001]
  • [Cites] JAMA. 1998 Jan 7;279(1):35-40 [9424041.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1069-75 [15809352.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1319-32 [15837816.001]
  • [Cites] Nat Med. 2005 Dec;11(12):1290-2 [16288280.001]
  • [Cites] Int Ophthalmol Clin. 2006 Spring;46(2):91-110 [16770157.001]
  • [Cites] J Infect Dis. 2000 Mar;181(3):872-80 [10720507.001]
  • [Cites] N Engl J Med. 2001 May 31;344(22):1668-75 [11386265.001]
  • [Cites] Curr Opin Immunol. 2001 Aug;13(4):458-64 [11498302.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):429-34 [12134147.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 6;94(21):1592-3 [12419778.001]
  • [Cites] Annu Rev Med. 2003;54:535-51 [12525683.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):781-90 [14523385.001]
  • [Cites] EMBO J. 2004 Jan 28;23(2):255-9 [14685277.001]
  • [Cites] N Engl J Med. 1989 Oct 26;321(17):1141-8 [2477702.001]
  • [Cites] Adv Immunol. 1989;47:187-376 [2683611.001]
  • [Cites] J Acquir Immune Defic Syndr. 1992;5(5):490-6 [1560346.001]
  • [Cites] Annu Rev Immunol. 1993;11:269-95 [8476562.001]
  • [Cites] AIDS. 1994 Aug;8(8):1123-8 [7986410.001]
  • [Cites] Annu Rev Immunol. 2005;23:225-74 [15771571.001]
  • (PMID = 16933987.001).
  • [ISSN] 1553-7374
  • [Journal-full-title] PLoS pathogens
  • [ISO-abbreviation] PLoS Pathog.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / R37 DA004334; United States / NIDA NIH HHS / DA / R56 DA004334; United States / NIDA NIH HHS / DA / R01 DA004334; United States / NIDA NIH HHS / DA / DA04334; United States / Intramural NIH HHS / / ; United Kingdom / Medical Research Council / / G9800943; United States / NCI NIH HHS / CA / N01CO12400; United Kingdom / Medical Research Council / / G0401569; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-B Antigens; 0 / Receptors, Immunologic; 0 / Receptors, KIR; 0 / Receptors, KIR3DS1
  • [Other-IDs] NLM/ PMC1550271
  •  go-up   go-down


92. Makombe SD, Harries AD, Yu JK, Hochgesang M, Mhango E, Weigel R, Pasulani O, Fitzgerald M, Schouten EJ, Libamba E: Outcomes of patients with Kaposi's sarcoma who start antiretroviral therapy under routine programme conditions in Malawi. Trop Doct; 2008 Jan;38(1):5-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIDS-associated Kaposi's sarcoma (KS) is the most common AIDS-related malignancy in sub-Saharan Africa, with a generally unfavourable prognosis.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18302849.001).
  • [ISSN] 0049-4755
  • [Journal-full-title] Tropical doctor
  • [ISO-abbreviation] Trop Doct
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  •  go-up   go-down


93. Vanni T, Sprinz E, Machado MW, Santana Rde C, Fonseca BA, Schwartsmann G: Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives. Cancer Treat Rev; 2006 Oct;32(6):445-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives.
  • Kaposi's sarcoma (KS) is the most frequent type of cancer in patients with Acquired Immune Deficiency Syndrome (AIDS).
  • In contrast, the incidence of KS has been steadily climbing in parallel with the AIDS epidemic in Africa over the past 10-15 years, being the most common cancer in adult men in countries like Uganda and Zimbabwe.
  • AIDS-KS can be diagnosed at any stage of HIV infection, although it more commonly occurs in the setting of severe immune suppression, especially with an elevated viral load.
  • Up to now, AIDS-KS is still an incurable disease.
  • Optimal anti-retroviral therapy is a key component of AIDS-KS management.
  • There are still many questions to be answered in the management of patients with AIDS-KS, such as (1) What are the therapeutic agents that should be used in this disease, and in which sequence?
  • The aim of this review is to discuss the systemic management of AIDS-KS, with special focus on the above mentioned questions.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860939.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antiviral Agents; 0 / Liposomes; 9008-11-1 / Interferons; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 78
  •  go-up   go-down


94. Crosswell HE, Bergsagel DJ, Yost R, Lew G: Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma. Pediatr Blood Cancer; 2008 Apr;50(4):883-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma.
  • Burkitt lymphoma is the most common AIDS-related lymphoma (ARL) in childhood.
  • We present a case of advanced stage Burkitt lymphoma in an 8-year-old female with acquired immunodeficiency syndrome (AIDS), who was successfully treated with a 3 month course of modified CHOP-R (cyclophosphamide, daunorubicin, vincristine, prednisone, and rituximab) and HAART therapy.
  • The combination of rituximab and chemotherapy with HAART therapy may be well-tolerated and effective in HIV/AIDS patients with Burkitt lymphoma.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 17278123.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


95. Bazoes A, Bower M, Powles T: Smoke and mirrors: HIV-related lung cancer. Curr Opin Oncol; 2008 Sep;20(5):529-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smoke and mirrors: HIV-related lung cancer.
  • PURPOSE OF REVIEW: The introduction of highly active antiretroviral therapy has dramatically reduced AIDS-related illnesses and increased life expectancy for people living with HIV infection.
  • At the same time, non-AIDS-defining cancers are becoming an increasing problem and now account for a large proportion of HIV-related deaths.
  • Perhaps the most important and controversial of these is HIV-related lung cancer.
  • RECENT FINDINGS: Smoking does not account for all of the increase in the incidence of lung cancer seen in HIV patients.
  • SUMMARY: HIV-related lung cancer is becoming an increasingly important problem as patients are living longer with HIV infection.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106655.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


96. Lim ST, Levine AM: Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma. CA Cancer J Clin; 2005 Jul-Aug;55(4):229-41; 260-1, 264
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma.
  • With the remarkable decrease in the incidence of opportunistic infections since the availability of highly active antiretroviral therapy (HAART), acquired immune deficiency syndrome-related lymphoma (ARL) is now the second most common cancer associated with human immunodeficiency virus after Kaposi sarcoma.
  • Nonetheless, several controversial issues persist, including the optimal timing of HAART with combination chemotherapy, the role of rituximab when incorporated into treatment regimens, and the optimal therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / physiopathology
  • [MeSH-minor] AIDS-Related Opportunistic Infections. Drug Administration Schedule. Humans. Incidence. Peripheral Blood Stem Cell Transplantation. Prevalence. Prognosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020424.001).
  • [ISSN] 0007-9235
  • [Journal-full-title] CA: a cancer journal for clinicians
  • [ISO-abbreviation] CA Cancer J Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


97. Vidrine DJ, Amick BC 3rd, Gritz ER, Arduino RC: Assessing a conceptual framework of health-related quality of life in a HIV/AIDS population. Qual Life Res; 2005 May;14(4):923-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing a conceptual framework of health-related quality of life in a HIV/AIDS population.
  • With the recognition of health-related quality of life (HRQOL) as an important outcome in the course of HIV-disease, it is important to gain a better understanding of the complex relationships among the various factors that influence it.
  • This study assesses a conceptual framework of HRQOL, consisting of disease status, socio-economic status (SES), behavioral variables, symptom status, role-specific functional status and HRQOL, among a multiethnic, economically disadvantaged population of individuals living with HIV/AIDS.
  • Self-report data were collected from 348 patients receiving care at a large HIV/AIDS care center, serving residents of a large metropolitan area.
  • This framework suggests that health-related variables fall along a continuum, beginning with disease status and ending in generic HRQOL.